

BA



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 442 448 A2

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 91101958.6

⑮ Int. Cl.5: C07D 207/327, C07D 237/14,
C07D 253/07, C07D 239/36,
C07D 233/72, C07D 257/04,
C07D 277/30, C07D 233/64,
C07D 231/12, C07D 233/84,
A61K 31/40, //A61K31/41,
A61K31/415, A61K31/425,
A61K31/50

⑭ Date of filing: 12.02.91

⑯ Priority: 13.02.90 US 479507
13.02.90 US 479508
13.02.90 US 479563
13.02.90 US 479561
13.02.90 US 479564
13.02.90 US 479559
13.02.90 US 479560
13.02.90 US 479506
20.06.90 US 540988
13.02.90 US 479505

AT BE CH DE DK ES FR GB GR IT LI LU NL SE

⑰ Applicant: Bristol-Myers Squibb Company
345 Park Avenue
New York, N.Y. 10154(US)

⑱ Inventor: Meanwell, Nicholas
2 Spice Hill Drive
East Hampton, Connecticut 06424(US)

⑲ Representative: Kinzebach, Werner, Dr. et al
Patentanwälte Reitstötter, Kinzebach und
Partner Sternwartstrasse 4 Postfach 86 06 49
W-8000 München 86(DE)

⑳ Date of publication of application:


21.08.91 Bulletin 91/34

㉑ Designated Contracting States:


㉒ Heterocyclic carboxylic acids and esters.

㉓ Heterocyclic acids and esters useful as inhibitors of mammalian blood platelet aggregation characterized by Formula I, II and VIII are disclosed.


EP 0 442 448 A2



(I)



(II)



(VIII)

Formula I compounds are those wherein n is 6-9, R is hydrogen, lower alkyl or an alkali metal ion, and HET₁ is heterocyclic radical selected from the group consisting of 3,4-diphenyl-1H-pyrrol-1-yl, 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl, 2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl, 1-oxo-4,5-diphenyl-2H-pyrimidin-1-yl, 2,5-dioxo-3,4-diphenylimidazolidin-1-yl, 5-(diphenylmethyl)-2H-tetrazol-2-yl, 4,5-diphenyl-2-thiazoyl, 4,5-diphenyl-1H-imidazol-2-yl, and 1,5-diphenyl-1H-pyrazol-3-yl.

Formula II compounds are those wherein R₁ is hydrogen, lower alkyl or an alkali metal ion, and the radical -OCH₂CO₂R₁ is attached in the 3 or 4 ring position; and HET₂ is a heterocyclic radical selected from the group consisting of 4,5-diphenyl-2-thiazoyl, 4,5-diphenyl-1H-imidazol-2-yl, 3,4-diphenyl-1H-pyrazol-1-yl, 4,5-diphenyl-1H-pyrazol-1-yl, 1-5-diphenyl-1H-pyrazol-3-yl, 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl, 2,3-dihydro-3-oxo-5,6-diphenylmethyl-1,2,3-triazin-2-yl, and 5-(diphenylmethyl)-2H-tetrazol-2-yl.

Formula VIII compounds are those wherein R₁ is hydrogen, lower alkyl or an alkali metal ion, and the radical -OCH₂CO₂R₁ is attached in the 3 or 4 ring position.


HETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS

BACKGROUND OF THE INVENTION


This invention generally pertains to heterocyclic carbon compounds having drug and bio-affecting properties and to their preparation and use. In particular, the invention is concerned with various heterocyclic derivatives characterized by Formulas I and II, infra, which are inhibitors of blood platelet aggregation.

United States patents relating to the carboxylic acid and ester derivatives of the various heterocycles disclosed herein are as follows:


(1) Pyrrole compounds in Field of Search 514/427, 428, and 548/562, 563.
 10 Chinn, U.S. Patent 3,471,513 discloses 2-(2-carboxyethyl)-5-phenyl-1-pyrrolebutyric acid and congeners with antibiotic and ulcer-inhibiting properties of formula (1)




20 Ohsumi, et al., U.S. Patent 4,336,194 discloses carboxylic acid esters having insecticidal properties of formula (2).



30 Maldonado, et al., U.S. Patent 4,563,477 discloses alpha-(N-pyrrolyl)-derivative acids having platelet antiaggregation and analgesic activity of formula (3).




45 Chinn, U.S. Patent 4,694,018 discloses substituted 1,5-diphenyl-2-pyrrolepropionic acids having 5-lipoxygenase inhibiting properties of formula (4).




(2) Pyridazine compounds in Field of Search 514/247 and 544/239.

King, et al. U.S. Patent 2,712,542 discloses 2-(3-pyridazonyl)-acids having analgesic, anticonvulsant, antispasmodic and sedative activities of formula (5).



Baetz. U.S. Patent 3,622,576 discloses diphenyl-pyridazones of formula (6) having psychotropic and analgesic properties.



40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

5510

5511

5512

5513

5514

5515

5516

5517

5518

5519

5520

5521

5522

5523

5524

5525

5526

5527

5528

5529

5530

5531

5532

5533

5534

5535

5536

5537

5538

5539

5540

5541

5542

5543

5544

5545

5546

5547

5548

5549

5550

5551

5552

5553

5554

5555

5556

5557

5558

5559

5560

5561

5562

5563

5564

5565

5566

5567

5568

5569

55610

55611

55612

55613

55614

55615

55616

55617

55618

55619

55620

55621

55622

55623

55624

55625

55626

55627

55628

55629

55630

55631

55632

55633

55634

55635

55636

55637

55638

55639

55640

55641

55642

55643

55644

55645

55646

55647

55648

55649

55650

55651

55652

55653

55654

55655

55656

55657

55658

55659

55660

55661

55662

55663

55664

55665

55666

55667

55668

55669

55670

55671

55672

55673

55674

55675

55676

55677

55678

55679

55680

55681

55682

55683

55684

55685

55686

55687

55688

55689

55690

55691

55692

55693

55694

55695

55696

55697

55698

55699

55700

55701

55702

55703

55704

55705

55706

55707

55708

55709

55710

55711

55712

55713

55714

55715

55716

55717

55718

55719

55720

55721

55722

55723

55724

55725

55726

55727

55728

55729

55730

55731

55732

55733

55734

55735

55736

55737

55738

55739

55740

55741

55742

55743

55744

55745

55746

55747

55748

55749

55750

55751

55752

55753

55754

55755

55756

55757

55758

55759

55760

55761

55762

55763

55764

55765

55766

55767

55768

55769

55770

55771

55772

55773

55774

55775

55776

55777

55778

55779

55780

55781

55782

55783

55784

55785

55786

55787

55788

55789

55790

55791

55792

55793

55794

55795

55796

55797

55798

55799

55800

55801

55802

55803

55804

55805

55806

55807

55808

55809

55810

55811

55812

55813

55814

55815

55816

55817

55818

55819

55820

55821

55822

55823

55824

55825

55826

55827

55828

55829

55830

55831

55832

55833

55834

55835

55836

55837

55838

55839

55840

55841

55842

55843

55844

55845

55846

55847

55848

55849

55850

55851

55852

55853

55854

55855

55856

55857

55858

55859

55860

55861

55862

55863

55864

55865

55866

55867

55868

55869

55870

55871

55872

55873

55874

55875

55876

55877

55878

55879

55880

55881

55882

55883

55884

55885

55886

55887

55888

55889

55890

55891

55892

55893

55894

55895

55896

55897

55898

55899

55900

55901

55902

55903

55904

55905

55906

55907

55908

55909

55910

55911

55912

55913

55914

55915

55916

55917

55918

55919

55920

55921

55922

55923

55924

55925

55926

55927

55928

55929

55930

55931

55932

55933

55934

55935

55936

55937

55938

55939

55940

55941

55942

55943

55944

55945

55946

55947

55948

55949

55950

55951

55952

55953

55954

55955

55956

55957

55958

55959

55960

55961

55962

55963

55964

55965

55966

55967

55968

55969

55970

55971

55972

55973

55974

55975

55976

55977

55978

55979

55980

55981

55982

55983

55984

55985

55986

55987

55988

55989

55990

55991

55992

55993

55994

55995

55996

55997

55998

55999

559100

559101

559102

559103

559104

559105

559106

559107

559108

559109

559110

559111

559112

559113

559114

559115

559116

559117

559118

559119

559120

559121

559122

559123

559124

559125

559126

559127

559128

559129

559130

559131

559132

559133

559134

559135

559136

559137

559138

559139

559140

559141

559142

559143

559144

559145

559146

559147

559148

559149

559150

559151

559152

559153

559154

559155

559156

559157

559158

559159

559160

559161

559162

559163

559164

559165

559166

559167

559168

559169

559170

559171

559172

559173

559174

559175

559176

559177

559178

559179

559180

559181

559182

559183

559184

559185

559186

559187

559188

559189

559190

559191

559192

559193

559194

559195

559196

559197

559198

559199

559200

559201

559202

559203

559204

559205

559206

559207

559208

559209

559210

559211

559212

559213

559214

559215

559216

559217

559218

559219

559220

559221

559222

559223

559224

559225

559226

559227

559228

559229

559230

559231

559232

559233

559234

559235

559236

559237

559238

559239

559240

559241

559242

559243

559244

559245

559246

559247

559248

559249

559250

559251

559252

559253

559254

559255

559256

559257

559258

559259

559260

559261

559262

559263

559264

559265

559266

559267

559268

559269

559270

559271

559272

559273

559274

559275

559276

559277

559278

559279

559280

559281

559282

559283

559284

559285

559286

559287

559288

559289


559290

559291


559292

559293


5 bogenic properties of formula (8).




15 Lacefield, U.S. Patent 4,318,911 discloses 5,6-diaryl-1,2,4-triazines having antithrombogenic activity of the formula (9).




25 Pitet, et al., U.S. Patent 4,511,566 discloses 2-N-cycloalkylmethyl-3-oxo-5,6-diaryl-as-triazines having analgesic activity of formula (10).




35 Guv, et al., U.S. Patent 4,677,105 discloses 2-alkoxycarbonylalkyl-3-oxo-5,6-diaryl-as-triazines having non-inflammatory analgesic activity of formula (11).




45 50 Pitit, et al., U.S. Patent 4,851,411 discloses 5-monoaryl as-triazin-3-ones having antianxiety or antidepressant activity of formula (12).




10 (4) Pyrimidine compounds in Field of Search 514/274 and 544/335.
 Caldwell, et al., U.S. Patent 4,486,443 discloses hydantoins having antithrombogenic properties of formula (13).




25 (5) Imidazolidine compounds in Field of Search 514/398 and 548/308, 312, 314.
 van der Burg, U.S. Patent 3,965,114 discloses imidazolidine derivatives having anticholinergic and anticonvulsant properties of formula (14).




40 Whootton, et al., U.S. Patent 4,237,131 discloses hydantoins having bronchodilator activity of formula (15).




50 Lautenschlager, et al., U.S. Patent 4,330,550 discloses omega-(2-oxo-4-imidazolin-1-yl)alkanoic acids and esters having antithrombogenic and analgesic activity of formula (16).



10 Mai, et al., U.S. Patent 4,709,042 discloses a process for preparing 2-(1-hydroxyalkyl)-5,5-diphenyl hydantoin of the formula (17).




Matsuno, et al., U.S. Patent 4,797,493 discloses imidazolines having ultraviolet-absorbing properties of formula (18).




(6) Tetrazole compounds in Field of Search 514/365 and 548/253.


Hayao, U.S. Patent 3,453,285 discloses tetrazolyl alkanoic acids having anti-inflammatory properties of formula (19).



50 Katner, U.S. Patent 3,962,272 discloses 1H-tetrazole-1-acetate esters and acids useful for preparing cephalosporin and penicillin antibiotics of formula (20)



6




(24)

10

Hepworth, et al., U.S. Patent 3,661,920 discloses thiazole derivatives having anti-inflammatory, analgesic and antipyretic activity of formula (25).

15




(25)

20

25

Malen, et al., U.S. Patent 3,821,237 discloses thiazolyl benzoic acid compounds having fibrinolytic, platelet stickiness decreasing and antiulcer properties of formula (26).

30




(26)

35

Malen, et al., U.S. Patent 3,840,548 discloses thiazolylbenzoic acid compounds having thrombolytic properties of formula (27).

40




(27)

45


Rynbrandt, et al., U.S. Patent 4,168,315 discloses dianisyl thiazole compounds having reduced platelet adhesiveness and inhibition of platelet aggregation properties of formula (28).

50


55




Yoshino, et al., U.S. Patent 4,659,726 discloses 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles having platelet aggregation inhibiting properties of formula (29).




Lutomski, et al., U.S. Patent 4,791,124 discloses oxazole and thiazole compounds having insecticidal properties of formula (30).




(8) Imidazole compounds in Field of Search 514/396 and 548/342.
Furukawa, et al., U.S. Patent 4,355,040 discloses imidazole-5-acetic acid derivatives having hypotensive properties of formula (31).




Lautenschlager, et al., U.S. Patent 4,460,598 discloses triphenylimidazolylalkanoic acids having antithrombogenic properties of formula (32).



Wareing, U.S. Patent 4,668,794 discloses imidazole acrolein analogs having blood cholesterol lowering properties of formula (33).




Bender, et al., U.S. Patent 4,686,231 discloses 4,5-diaryl-2(substituted)-imidazoles having 5-lipoxygenase inhibiting properties of formula (34).




(9) Pyrazole compounds in Field of Search 514/406 and 548/378.


Noguchi, et al., U.S. Patent 3,704,241 discloses 4-pyrazole acetic acid or esters having anti-inflammatory and analgesic properties of formula (35).




Ahrens, et al., U.S. Patent 4,042,706 discloses pyrazole derivatives having anti-inflammatory properties of formula (36).




Rainer, U.S. Patent 4,146,721 discloses pyrazol-4-acetic acids having analgesic, anti-inflammatory and antipuretic properties of formula (37).




Beck, et al., U.S. Patent 4,495,195 discloses 3(5)-phenyl-substituted-5(3)-pyrazole-carboxylic acids having xanthine oxidase inhibiting properties of formula (38).




10 Wareing, U.S. Patent 4,613,610 discloses pyrazole analogs having cholesterol biosynthesis inhibiting properties of mevalonolactone of formula (39).




20 Wachter, et al., U.S. Patent 4,826,868 discloses 1,5-diaryl-3-substituted pyrazoles which inhibit cyclooxygenase enzyme and lipoxygenase enzyme pathways of formula (40).



30 Takamura, et al., U.S. Patent 4,853,404 discloses 5-pyrazolylphenoxy acetic acids having diuretic, saluretic, and uricosuric properties of formula (41).



40 Bailey, U.S. Patent 4,870,095 discloses antiarrhythmic 1H-pyrazole-1-alkanamides of formula (42).




15 SUMMARY OF THE INVENTION

In its broadest aspect, this invention is concerned with heterocyclic carboxylic acids and esters of Formula I and Formula II

20



25



30

wherein Het₁, Het₂, R, R₁, and n are defined below which are inhibitors of adenosine diphosphate and collagen-induced aggregation of human platelet-rich plasma and are particularly useful as inhibitors of mammalian blood platelet aggregation.

35 Another embodiment of the invention relates to the alkali metal salts of carboxylic acids of Formula I (R is hydrogen) and Formula II (R₁ is hydrogen). A further embodiment concerns pharmaceutical compositions comprised of a Formula I or II compound combined with at least one pharmaceutically acceptable excipient. Yet another embodiment relates to a method for inhibiting blood platelet aggregation in a mammal which comprises administering a therapeutically effective amount of a compound of Formula I or an alkali metal 40 salt thereof where R is hydrogen or a Formula II compound or an alkali metal salt thereof where R₂ is hydrogen to a mammal in need of such treatment.


DETAILED DESCRIPTION OF THE INVENTION

45 This invention relates to inhibitors of mammalian blood platelet aggregation OF Formula I




wherein n is 6-9, R is hydrogen, lower alkyl or an alkali metal ion, and HET₁ is a heterocyclic radical 50 selected from the group consisting of

55




5

(a) 3,4-diphenyl-1H-pyrrol-1-yl,




10

(b) 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl,




15

(c) 2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl,




20

(d) 1-oxo-4,5-diphenyl-2H-pyrimidin-1-yl,




25



30


(e) 2,5-dioxo-3,4-diphenylimidazolidin-1-yl,

(f) 5-(diphenylmethyl)-2H-tetrazol-2-yl,




40

(g) 4,5-diphenyl-2-thiazoyl,



45


(h) 4,5-diphenyl-1H-imidazol-2-yl, and



50

(i) 1,5-diphenyl-1H-pyrazol-3-yl.

The compounds of the instant invention are further characterized by Formula II




10 wherein


R_1 is hydrogen, lower alkyl or an alkali metal ion, and the radical $-\text{OCH}_2\text{CO}_2\text{R}$ is attached in the 3 or 4 ring position;

HET_2 is a heterocyclic radical selected from the group consisting of

15



(a) 4,5-diphenyl-2-thiazoyl.



(b) 4,5-diphenyl-1H-imidazol-2-yl,

30

35

40


45

50

55




(c) 3,4-diphenyl-1H-pyrazol-1-yl,




(d) 4,5-diphenyl-1H-pyrazol-1-yl,

10




20 (e) 1,5-diphenyl-1H-pyrazol-3-yl,




(f) 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl,

25



35

(g) 2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl, and



(h) 5-(diphenylmethyl)-2H-tetrazol-2-yl.

It is understood that as used herein limitations of Formula I and II are defined as follows.

The term "lower alkyl" refers to a branched or unbranched saturated hydrocarbon chain containing from 40 1-4 carbon atoms; specifically, methyl, ethyl, n-propyl, isopropyl, n-butyl, secondary butyl, and tertiary butyl.

The term "lower alkanol" denotes an alcohol having 1-4 carbon atoms defined by "lower alkyl".

The symbol "Ph" represents phenyl.

The term "alkali metal ion" refers to ions derived from the alkali metals, most preferably sodium and potassium.


45 According to the present invention the compounds characterized by Formula I are obtained by a process comprising:

(a) hydrolyzing a compound of Formula (I^a)




wherein HET₁ is as defined above, n is 6-9 and R^a is lower alkyl, or

(b) esterifying a compound of Formula (I^b)



wherein HET₁ is as defined above and n is 6-9 with a lower alkanol, or


(c) alkylating HET₁-H wherein HET₁ is as defined above with a compound of Formula (III)



wherein X is halogen, preferably bromine, n is 6 to 9, and R^a is lower alkyl.
 Scheme 1 below illustrates the foregoing process.

5

Scheme 1




Compounds of Formula I are conventionally prepared as shown in Scheme 1 by base-mediated alkylation of the parent heterocycle (III) with a lower alkanol ester of an omega-halogenalkanoic acid (IV) to provide esters (I^a). Alkylation can be carried out with sodium hydride, potassium hydride, potassium t-butoxide in suitable solvents such as tetrahydrofuran and dimethylformamide with conditions dependent upon the identity of the heterocycle and the acidity of the proton being replaced. Preferred alkylating conditions employ sodium hydride in dimethylformamide (DMF) at room temperature or potassium carbonate in DMF at 110°C. In those instances where the alkylation results in mixtures of regioisomers, separation is readily accomplished by chromatography on silica gel. Structural assignments are made from consideration of the ¹H and ¹³C NMR spectra. The heterocycles (III) employed as starting material are synthesized by methods reported in the chemical literature or by minor modifications thereof readily apparent to a skilled chemist.

Esters (I^a) are converted to the corresponding acids (I^b) under the influence of either aqueous alkali or aqueous acid depending upon the sensitivity of the heterocycle. Conversely, acids (I^b) are conventionally converted to the corresponding esters (I^a) by heating the acid in a lower alkanol in the presence of an inorganic acid such as hydrochloric, sulfuric and the like.


Alkali metal salts of Formula I carboxylic acids (R is an alkali metal ion) are conventionally prepared by dissolving the acid in a suitable solvent such as methanol, adding a molar equivalent of an alkali base such as sodium methoxide, and precipitating the salt or removing the solvent.

According to the present invention, the compounds characterized by Formula II are obtained by a process comprising:

(a) hydrolyzing a compound of Formula II^a




wherein HET₂ is as defined above and R₁^a is lower alkyl; or
 (b) esterifying a compound of Formula II^b




15

wherein HET₂ is as defined above; or
 (c) alkylating HET₂-H wherein HET₂ is as defined above with a compound of Formula (V)




25

wherein R₁^a is lower alkyl and X is halogen or an aryl sulfonate; or
 (d) alkylating a compound of Formula (VI)



35


wherein HET₂ is as defined above with BrCH₂CO₂R₁ wherein R₁^a is lower alkyl; or
 (e) hydrolyzing a compound of Formula VII




45

wherein R₁^a is as defined above.
 The following schemes for preparation of representative compounds of Formula II illustrate the foregoing process.


Scheme 2




Scheme 3



Scheme 4



Scheme 5



45 Scheme 2 depicts several different approaches for synthesis of compounds incorporating the aryloxacetic acid moiety. Direct alkylation of heterocycle (1) with either bromide (2) or tosylate (TS) (3) available from alcohol (5), was accomplished with sodium hydride in DMF at room temperature or potassium carbonate in DMF at 110 °C to furnish esters (6). Alternatively, in some cases, reaction of the heterocycle (1) with alcohol (5) obtained from diol (4) in the presence of diethyl azodicarboxylate and triphenylphosphine provided esters (6) under the mild conditions characteristic of the Mitsunobu reaction, *Synthesis*, 1-28 (1981). Carboxylic acids (7) were obtained by alkaline hydrolysis of esters (6).

50 Scheme 3 depicts the synthesis of thiazole derivatives (12) and (13) wherein the aryloxacetic acid side chain is appended to a carbon. Metallation of 2-methyl-4,5-diphenylthiazole (8) with *n*-butyllithium followed by quenching with bromide (9) provided the silyl ether (10) which was deprotected with tetra-*n*-butylammonium fluoride to give phenol (11). Alkylation of phenol (11) with methyl bromoacetate gave ester (12) which was hydrolyzed to the acid (13) under aqueous alkaline conditions.

55 Scheme 4 depicts preparation of Formula II imidazole derivatives (19) and (20) wherein the aryloxacetic acid side chain is also appended to a carbon. The synthesis was carried out in a manner analogous

to Scheme 3 but the presence of an active hydrogen in 2-methyl-4,5-diphenylimidazole (14) necessitated introduction of a protecting group onto one of nitrogen atoms prior to metallation. Various protecting groups known to those skilled in the art can be used with the ethoxyethyl moiety described by T.S. Manoharan, et al., *J. Org. Chem.*, 53, 1107-1110 (1988), particularly preferred as it has the advantage of being inexpensive and easily introduced. Heating 2-methyl-4,5-diphenylimidazole (14) with an excess of ethyl vinyl ether in a sealed reaction vessel provided the crystalline N-(1-ethoxyethyl) imidazole (15). Metallation of imidazole (15) with n-butyllithium followed by reaction with bromide (9) provided silyl ether (16). Selective removal of the silyl protecting group was accomplished by exposing (16) to tetra-n-butylammonium fluoride. Alkylation of phenol (17) with methyl bromoacetate afforded ester (18) which was converted to the imidazole (19) by heating in methanol in the presence of concentrated sulfuric acid. Aqueous alkaline hydrolysis gave acid (20).

Scheme 5 depicts preparation of Formula II pyrazoles (25) and (26). Alkylation of the dianion of 1-benzoylacetone (21) with bromide (9) afforded diketone (22). Exposure of (22) to phenylhydrazine provided pyrazole (23). Removal of the silyl protecting group of (23) with tetra-n-butylammonium fluoride and subsequent alkylation of phenol (24) with methyl bromoacetate gave ester (25). Base-induced hydrolysis of ester (25) provided the target acid (26).

Alkali metal salts of Formula II carboxylic acids (R¹ is an alkali metal ion) are conventionally prepared by dissolving the acid in a suitable solvent such as methanol, adding a molar equivalent of an alkali base such as sodium methoxide, and precipitating the salt or removing the solvent.

As stated above, the compounds of Formula I and Formula II have pharmacological properties which make them particularly useful as inhibitors of blood platelet aggregation.

Platelet aggregation is considered part of a complex physiological mechanism for formation of a thrombus in the vascular system. Thromboembolic phenomena, i.e., the formation of thrombi, are involved in hemostasis and a number of disease states in mammals including thrombophlebitis, phlebothrombosis, cerebral thrombosis, coronary thrombosis and retinal vessel thrombosis. An increase in propensity for platelet aggregation, sometimes referred to as platelet adhesiveness, is observed following parturition, surgical operations such as coronary artery bypass surgery, organ transplant, angioplasty, prosthetic heart valve implants to name a few and in ischaemic heart disease, atherosclerosis, multiple sclerosis, intracranial tumors, thromboembolism, and hyperlipemia; refer to A. Poplawski, et al., *J. Atherosclerosis Research*, 8, 721 (1968). Thus, the compounds of the invention which have antithrombogenic actions (inhibit blood platelet aggregation) are useful in prevention or treatment of conditions involving platelet aggregation and thrombosis such as the above. The instant compounds are also considered to have antimetastatic potential in view of their platelet inhibition properties.

The pharmacological properties of the instant compounds can be demonstrated by conventional in vitro and in vivo biological tests such as the following.

IN VITRO INHIBITION OF HUMAN PLATELET AGGREGATION

The aggregometer method of Born, C.V.R., *J. Physiol.*, (London), 1962, 162, 67-68, as modified by Mustard, J.F., et al., *J. Lab. Clin. Med.* 1964, 64, 548-559 was used to assess the in vitro activity of the various compounds as to the inhibition of adenosine diphosphate (ADP) and collagen-induced platelet aggregation. The human volunteer donor's arm is cleansed with 70% ethyl alcohol. A sterile 20 ml syringe and needle are used to withdraw 20 ml of blood. The blood is immediately added to a test tube containing 3.8% sodium citrate to prevent clotting (1 part citrate to 9 parts blood).

Platelet rich plasma (PRP) was separated by centrifugation for 10 minutes at 1000 rpm (140xg) from citrated (3.8%) human blood. All glassware used for preparation of PRP is silicon treated. ADP in final concentration of 0.5 mcg/mL or 0.05 mL of a collagen suspension prepared according to the method described by Evans, G., et al., *J. Exp. Med.*, 1968, 128, 877-894 was used to induce aggregation. The various compounds tested were dissolved in dimethylsulfoxide (DMSO) so that 5 mcL added to the platelet rich plasma would yield the desired test concentration. Vehicle control trials were done and compared with aggregation induced in platelet rich plasma containing various concentrations of the test compounds. Dose response curves were obtained and Inhibitor Concentration (IC₅₀) values calculated. In this test, the IC₅₀ values for dipyridamole, a clinically useful antithrombogenic agent, are 512 mcg/ml vs. ADP and 245 mcg/ml vs collagen. Results for 50% inhibition of ADP-induced aggregation are given in Tables I and II hereinafter for various Formula I and II compounds.


5

TABLE I
Inhibition of Human Platelet Aggregation
of Formula I Compounds (IC_{50} mcg/ml)

10

Example	HET ₁	n	R	vs. ADP mcg/ml
1	3,4-diphenyl-1H-pyrrol-1-yl	8	CH ₃	32
2		8	H	4
15				
3	1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl	8	CH ₃	21
4		8	H	2.9
20				
5	1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl	7	CH ₃	7.7
6		7	H	1.6
25				
7	2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl	8	CH ₃	6.8
8		8	H	2.2
30				
9	2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl	7	CH ₃	4.6
10		7	H	3.1
35				
11	2-oxo-4,5-diphenyl-2H-pyrimidin-1-yl	8	CH ₃	> 32
12		8	H	12
40				
13	2-oxo-4,5-diphenyl-2H-pyrimidin-1-yl	7	CH ₃	> 32
14		7	H	10
45				
15	2,5-dioxo-3,4-diphenyl-imidazolidin-1-yl	8	CH ₃	> 32
16		8	H	11.9
50				
17	5-(diphenylmethyl)-2H-tetrazol-2-yl	8	CH ₃	> 32
18		8	H	4.2

TABLE 2
Inhibition of Human Platelet Aggregation
of Formula II Compounds (IC_{50} mcg/ml)



Example	HET ₂	R ₁	Vs ADP mcg/ml
19	4,5-diphenyl-1-thiazoyl	CH ₃	0.41
20	4,5-diphenyl-1H-imidazol-2-yl	H	0.36
21	4,5-diphenyl-1H-pyrazol-1-yl	CH ₃	2.4
22	3,4-diphenyl-1H-pyrazol-1-yl	H	1.2
23	4,5-diphenyl-1H-pyrazol-1-yl	CH ₃	0.21
24	4,5-diphenyl-1H-pyrazol-1-yl	H	0.35
25	1,5-diphenyl-1H-pyrazol-3-yl	CH ₃	0.20
26	1,5-diphenyl-1H-pyrazol-3-yl	H	0.30
27	1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl	CH ₃	0.33
28	1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl	H	0.67
29	2,3-dihydro-3-oxo-5,6-diphenyl-1,4-triazin-2-yl	CH ₃	0.75
30	2,3-dihydro-3-oxo-5,6-diphenyl-1,4-triazin-2-yl	H	1.0
31	5-(diphenylmethyl)-2H-tetrazol-1-yl	CH ₃	0.9
32	5-(diphenylmethyl)-2H-tetrazol-1-yl	H	1.4
33			

It is evident that, as a group, the Formula I and II acids are particularly potent inhibitors of ADP-induced aggregation of human platelets. While the esters are generally less active than the parent acid, they are useful as pro-drugs *in vivo* where they are hydrolyzed to the corresponding acid.

The dosage employed in the therapeutic methods of the instant invention will vary with the form of administration, the particular compound chosen, the subject being tested and the effect desired. Suitable parenterally (generally characterized as subcutaneous, intramuscular, and intravenous) doses in animals range from 0.1-50 mg/kg body weight orally and from 0.05-10 mg/kg body weight mg administered one to three times a day. In accordance with conventional clinical practice, the dose can be determined by administering a Formula I or II compound at a dosage substantially less than the dose of the compound which is thought to be effective and then increasing the dosage in small increments until the desired effect is achieved.

In carrying out the instant therapeutic methods, the active ingredient of Formula I or II or alkali metal salts of Formula I and II carboxylic acids are preferably administered with a pharmaceutically acceptable carrier and such compositions constitute part of the instant invention. Suitable dosage forms for oral use are tablets, dispersible powders, granules, capsules, syrups and elixirs. Examples of parenteral forms are 5 solutions, suspension, dispersions, emulsions, and the like. The compositions for oral use may contain one or more conventional adjuvants, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a composition of suitable pharmaceutical elegance. Tablets may contain the active ingredient in admixture with conventional pharmaceutical acceptable excipients including inert diluents such as calcium carbonate, sodium carbonate, lactose and talc; granulating and disintegrating 10 agents such as starch and alginic acid; binding agents such as starch, gelatin and acacia and lubricating agents such as magnesium stearate, stearic acid and talc. The tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. Similarly, suspension, syrups and elixirs may contain the active ingredient in admixture with any of the conventional excipients utilized for the preparation of such 15 compositions such as suspending agents (e.g., methylcellulose, tragacanth, and sodium alginate), wetting agents (e.g., lecithin, polyoxyethylene stearate) and preservatives such as ethyl-p-hydroxybenzoate. Capsules may contain the active ingredient alone or admixed with an inert solid diluent such as calcium carbonate, calcium phosphate and kaolin. The injectable compositions are formulated as known in the art and may contain appropriate dispersing or wetting agents and suspending agents identical or similar to 20 those mentioned above.

The following examples are given by way of illustration and are not to be construed as limiting the invention in any way inasmuch as many variations of the invention are possible within the spirit of the invention.


25 DESCRIPTION OF SPECIFIC EMBODIMENTS

In the following examples, all temperatures are given in degrees Centigrade. Melting points were recorded on a Thomas-Hoover capillary melting point apparatus and are uncorrected. Proton magnetic resonance (¹H-NMR) spectra were recorded on a Bruker AM 300, Bruker WM 360 or Varian Gemini 300 30 spectrometer. All spectra were determined in CDCl₃ or DMSO-d₆ unless otherwise indicated and chemical shifts are reported in delta units downfield from the internal standard tetramethylsilane (TMS) and interproton coupling constants are reported in Hertz (Hz). Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak; and dd, doublet of doublet.

35 EXAMPLE 1

Methyl 3,4-diphenyl-1H-pyrrole-1-nonanoate

40



45

Sodium hydride (789 mg of a 50% dispersion in oil, 16mmol) was washed twice with hexanes and covered with DMF (40mL). 3,4-Diphenylpyrrole (3g, 13mmol), obtained according to K.R. Kopecky, et al., 50 Can. J. Chem., 54, 2645-2651 (1976), was added and the mixture stirred at room temperature until gas evolution ceased. Methyl-9-bromononanoate (3.81g, 14mmol) was added and stirring continued at room temperature. After 15 minutes, the mixture was poured onto 1N hydrochloric acid solution and extracted with diethyl ether (3x). The combined extracts were washed with water (3x), dried over sodium sulfate and concentrated in vacuo to leave an oil which was chromatographed on a column of silica gel. Elution with a 55 mixture of hexanes and diethyl ether (9:1) afforded methyl 3,4-diphenyl-1H-pyrrole-1-nonanoate (3.70g, 69%) as an oil.

Anal. Calcd. for C₂₆H₃₁NO₂: C, 80.17; H, 8.02; N, 3.60. Found: C, 79.84; H, 8.02; N, 3.36%.


¹H-NMR (CDCl₃) delta: 1.20 to 1.50 (8H, m), 1.60 (2H, m), 1.82 (2H, quintet, J=7Hz), 2.29 (2H, t,

J = 8Hz), 3.64 (3H, s), 3.87 (2H, t, *J* = 7Hz), 6.74 (2H, s), 7.20 to 7.60 (10H, m).

EXAMPLE 2

5 3,4-Diphenyl-1H-pyrrole-1-nonanoic Acid

10



15

A mixture of methyl 3,4-diphenyl-1H-pyrrole-1-nonanoate (2.50g, 6.4mmol), 5N sodium hydroxide solution (3.86mL, 19mmol) and methanol (50mL) was heated on a steam bath. After 30 minutes, the solvent was evaporated, the residue diluted with 1N HCl solution and extracted with CH_2Cl_2 . The combined extracts were dried over sodium sulfate, concentrated in vacuo and the residual oil chromatographed on a column of silica gel. Elution with a mixture of diethyl ether and hexanes (3:2) gave 3,4-diphenyl-1H-pyrrole-1-nonanoic acid (2.20g, 91%) as an oil.


Anal. Calcd. for $\text{C}_{25}\text{H}_{29}\text{NO}_2\cdot 0.7\text{H}_2\text{O}$: C, 77.37; H, 7.90; N, 3.61; H_2O , 3.25. Found: C, 77.23; H, 7.52; N, 3.42; H_2O , 0.43%.

25 $^1\text{H-NMR}$ (CDCl_3) delta: 1.42 (8H, bs), 1.72 (2H, quintet, *J* = 7Hz), 1.89 (2H, quintet, *J* = 7Hz), 2.42 (2H, t, *J* = 7Hz), 3.92 (2H, t, *J* = 7Hz), 6.83 (2H, s), and 7.20 to 7.40 (10H, m).

EXAMPLE 3

30 Methyl 6-oxo-3,4-diphenyl-1(6H)-pyridazinenonanoate

35



40


Sodium hydride (840mg of a 60% dispersion in oil, 20mmol) was washed twice with hexanes, covered with DMF (25mL) and 5,6-diphenyl-3(2H)-pyridazinone (4g, 16mmol), obtained according to P. Schmidt, et al., *Helvetica Chim. Acta.*, 37, 134-140 (1954), added. After gas evolution had ceased, the mixture was stirred at room temperature for 30 minutes before adding methyl 9-bromononanoate (4.45g, 18mmol). The mixture was heated briefly to 110 °C to give a solution and then allowed to cool before being stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with diethyl ether (3x). The combined extracts were washed with water, dried over sodium sulfate and concentrated to leave an oil. Chromatography on a column of silica gel afforded methyl 6-oxo-3,4-diphenyl-1(6H)-pyridazine nonanoate (6.44g, 95%) as an oil.

45 Anal. Calcd. for $\text{C}_{26}\text{H}_{30}\text{N}_2\text{O}_3$: C, 74.61; H, 7.22; N, 6.69. Found: C, 74.89; H, 7.38; N, 7.23%.
 $^1\text{H-NMR}$ (CDCl_3) delta: 1.20 to 1.45 (8H, m), 1.56 (2H, quintet, *J* = 7Hz), 1.85 (2H, quintet, *J* = 7Hz), 2.23 (2H, t, *J* = 7.5Hz), 3.59 (3H, s), 4.20 (2H, t, *J* = 7Hz), 6.88 (1H, s) and 7.00 to 7.40 (10H, m).

EXAMPLE 4

55

6-Oxo-3,4-diphenyl-1(6H)-pyridazinenonanoic acid




10 A mixture of methyl 6-oxo-3,4-diphenyl-1(6H)-pyridazinenonanoate (6g, 14mmol), 5N NaOH solution (8.6mL, 43mmol) and methanol (100mL) was heated to reflux on a steam bath. After 30 minutes, the mixture was concentrated, diluted with water and acidified to pH = 1 with 2N HCl solution. The mixture was extracted with CH₂Cl₂, the combined extracts dried over sodium sulfate and concentrated to leave an oil that
 15 crystallized on standing. Recrystallization from a mixture of CH₂Cl₂ and hexanes gave 6-oxo-3,4-diphenyl-1(6H)-pyridazinenonanoic acid (3.92g, 67%) mp 100-103 °C.

Anal. Calcd. for C₂₅H₂₈N₂O₃: C, 74.23; H, 6.98; N, 6.93. Found: C, 74.25; H, 7.13; N, 7.11%.

1H-NMR (CDCl₃) delta: 1.20 to 1.50 (8H, m), 1.59 (2H, t), 1.87 (2H, quintet, J = 6.5Hz), 2.29 (2H, t, J = 7Hz), 4.24 (2H, t, J = 7Hz), 6.98 (1H, s), 7.00 to 7.40 (10H, m) and 9.83 (1H, bs).

20 EXAMPLE 5

Methyl 6-Oxo-3,4-diphenyl-1(6H)pyridazinyloctanoate




30 Reaction of 5,6-diphenyl-3(2H)-pyridazone and methyl 8-bromooctanoate according to the procedure of Example 3 provided the title compound as an oil.

Anal. Calcd. for C₂₅H₂₈N₂O₃: C, 74.23; H, 6.98; N, 6.93. Found: C, 74.23; H, 7.27; N, 7.34.

EXAMPLE 6

40 6-Oxo-3,4-diphenyl-1(6H)-pyridazinyloctanoic Acid




50 Hydrolysis of methyl 6-oxo-3,4-diphenyl-1(6H)-pyridazinyloctanoate according to the procedure of Example 4 provided the title compound, m.p. 108-111 °C.

Anal. Calcd. for C₂₄H₂₆N₂O₃·0.2H₂O: C, 73.15; H, 6.76; N, 7.11; H₂O, 0.91. Found: C, 73.20; H, 6.69; N, 7.13; H₂O, 1.16

EXAMPLE 7

Methyl 3-oxo-5,6-diphenyl-1,2,4-triazine-2(3H)-nonanoate

5



10

Sodium hydride (577mg of a 60% dispersion in oil, 14mmol) was washed twice with hexanes, covered with DMF (40mL) and 5,6-diphenyl-1,2,4-triazol-3(2H)-one (3g, 12mmol), obtained according to M. Friedman, J. Org. Chem., 30, 859-863 (1965), added. After gas evolution ceased, the mixture was stirred for 15 minutes before adding methyl 9-bromononanoate (3.32g, 13mmol). The mixture was stirred at room temperature for 15 minutes, before being poured onto water and extracted with diethyl ether (3x). The combined extracts were washed with water (3x), dried over sodium sulfate and concentrated to leave an oil which was chromatographed on a column of silica gel. Elution with a mixture of diethyl ether and hexanes (3:2) gave methyl-3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-nonanoate (3.09g, 61%).


Anal. Calcd. for $C_{25}H_{29}N_3O_3$: C, 71.58; H, 6.97; N, 10.02. Found: C, 71.59; H, 7.13; N, 10.06%.

1H -NMR ($CDCl_3$) delta: 1.20 to 1.45 (8H, m), 1.58 (2H, quintet, $J = 6$ Hz), 1.90 (2H, quintet, $J = 6$ Hz), 2.26 (2H, t, $J = 6$ Hz), 3.63 (3H, s), 4.21 (2H, t, $J = 6$ Hz) and 7.20 to 7.55 (10H, m).

25 EXAMPLE 8

3-Oxo-5,6-diphenyl-1,2,4-triazine-2(3H)-nonanoic acid

30



35

40 A mixture of methyl-3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-nonanoate (1.90g, 4.5mmol), 5N NaOH solution (2.72mL, 13mmol) and methanol (30mL) was heated on a steam bath for 30 minutes. The volatiles were removed in vacuo and the residue diluted with water and dilute HCl solution until pH = 1. The mixture was extracted with CH_2Cl_2 , the combined extracts dried over sodium sulfate and concentrated to give an oil. Chromatography on a column of silica gel using diethyl ether as eluent gave 3-oxo-5,6-diphenyl-1,2,4-triazine-2(1H)-nonanoic acid (1.50g, 81%) which crystallized on standing and had mp 97-100 °C.


45 Anal. Calcd. for $C_{24}H_{27}N_3O_3$: C, 71.09; H, 6.71; N, 10.36. Found: C, 71.29; H, 6.97; N, 10.21%.

1H -NMR ($CDCl_3$) delta: 1.20 to 1.50 (8H, m), 1.57 (2H, t, $J = 7$ Hz), 1.88 (2H, quintet, $J = 7$ Hz), 2.27 (2H, t, $J = 7.5$ Hz), 4.19 (2H, t, $J = 7$ Hz), 7.20 to 7.60 (10H, m) and 10.89 (1H, bs).

50 EXAMPLE 9


Methyl 3-Oxo-5,6-diphenyl-1,2,4-triazine-2(3H)-octanoate

55




10 Reaction of 5,6-diphenyl-1,2,4-triazol-3(2H)one and methyl 8-bromooctanoate according to the procedure of Example 7 provided the title compound as an oil
Anal. Calcd. for $C_{24}H_{27}N_3O_3$: C, 71.09; H, 6.71; N, 10.36. Found: C, 71.05; H, 6.87; N, 10.41.

15 EXAMPLE 10

3-Oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-octanoic Acid

Hydrolysis of methyl 3-oxo-5,6-diphenyl-1,2,4-triazine-2(3H)-octanoate according to the procedure of
30 Example 8 provided the title compound, m.p. 111-113 °C.
Anal. Calcd. for $C_{23}H_{25}N_3O_3$: C, 70.57; H, 6.44; N, 10.73. Found: C, 70.35; H, 6.72; N, 10.33.


EXAMPLE 11

35 Methyl 2-Oxo-4,5-diphenyl-1(2H)-pyrimidinenonanoate

45 A mixture of 4,5-diphenyl-2(1H)-pyrimidinone (6.00g, 24mmol) obtained according to G.M. Coppola, et al., J. Het. Chem., 16, 545-554 (1979), methyl 9-bromononanoate (6.37g, 25mmol), potassium carbonate (4.00g, 29mmol) potassium iodide (catalytic quantity) and DMF (120mL) was stirred at 110 °C under an atmosphere of nitrogen. After 30 minutes, the mixture was cooled, diluted with water and extracted three times with diethyl ether. The combined extracts were washed with water (3x), dried over sodium sulfate and the solvent evaporated. The residual oil was chromatographed on a column of silica gel using diethyl ether as eluent to give methyl 9-[4,5-diphenyl]-2-pyrimidinyl]oxy]nonanoate (3.27g, 32%) as an oil and then with further elution methyl-2-oxo-4,5-diphenyl-1(2H)-pyrimidinenonanoate (6.00g, 59%) as an oil.
50 Anal. Calcd. for $C_{26}H_{30}N_2O_3$: C, 74.61; H, 7.22; N, 6.69. Found: C, 74.94; H, 7.38; N, 6.89%.

55 1H -NMR (CDCl₃) delta: 1.20 to 1.45 (8H, m), 1.56 (2H, quintet, $J = 7$ Hz), 1.81 (2H, quintet, $J = 7$ Hz), 2.24 (2H, t, $J = 7$ Hz), 3.60 (3H, s), 3.94 (2H, t, $J = 7$ Hz), 6.95 to 7.45 (10H, m) and 7.61 (1H, s).

EXAMPLE 12

2-Oxo-4,5-diphenyl-1(2H)-pyrimidinenonanoic Acid


10 A mixture of methyl 2-oxo-4,5-diphenyl-1(2H)-pyrimidinenonanoate (4.70g, 11mmol), 5N NaOH solution (7.40mL, 36mmol) and methanol (80mL) was stirred at room temperature for 75 minutes and then at reflux for 75 minutes before being cooled and concentrated. The residue was diluted with water and 2N HCl was added until pH=2. The mixture was extracted with CH_2Cl_2 , the extracts combined, dried over sodium sulfate and the solvent evaporated to leave an oil that crystallized. Recrystallization from a mixture of diethyl ether and CH_2Cl_2 afforded 2-oxo-4,5-diphenyl-1(2H)-pyrimidinenonanoic acid (3.35g, 73%), m.p. 120-123 °C.

15 Anal. Calcd. for $\text{C}_{25}\text{H}_{28}\text{N}_2\text{O}_3$: C, 74.23; H, 6.98; N, 6.93. Found: C, 74.22; H, 7.08; N, 6.61%.
¹H-NMR (CDCl_3) delta: 1.20 to 1.50 (8H, m), 1.56 (2H, bt), 1.80 (2H, bt), 2.27 (2H, t, J = 7Hz), 3.94 (2H, t, J = 7Hz), 6.95 to 7.55 (10H, m); 7.65 (1H) and 10.56 (1H, bs).

EXAMPLE 13

Methyl 2-Oxo-4,5-diphenyl-1(2H)-pyrimidineoctanoate

25



35 Reaction of 4,5-diphenyl-2(1H)-pyrimidinone and methyl 8-bromo-octanoate according to the procedure of Example 11 provided the title compound, m.p. 80-83 °C.


Anal. Calcd. for $\text{C}_{25}\text{H}_{28}\text{N}_2\text{O}_3$: C, 74.23; H, 6.98; N, 6.93. Found: C, 74.64; H, 7.21; N, 7.00.

EXAMPLE 14

40

2-Oxo-4,5-diphenyl-1(2H)-pyrimidineoctanoic Acid

45



50


Hydrolysis of methyl 2-oxo-4,5-diphenyl-2(1H)-pyrimidineoctanoate according to the procedure of Example 12 provided the title compound, m.p. 121-123 °C.

Anal. Calcd. for $\text{C}_{24}\text{H}_{26}\text{N}_2\text{O}_3$: C, 73.82; H, 6.71; N, 7.17. Found: C, 73.43; H, 6.83; N, 7.28.

55

EXAMPLE 15

Methyl 2,5-dioxo-3,4-diphenyl-1-imidazolidinenonanoate



10

Diethyl azodicarboxylate (1.39g, 8mmol) in THF (5mL) was added dropwise to a stirred solution of methyl 9-hydroxy-10-oxononanoate (1.50g, 8mmol), 3,4-diphenylimidazolidine-2,5-dione (2.02g, 8mmol) obtained according to the procedure of K.C. Joshi, et al., J. Het. Chem., 18, 1651-1653 (1981) and triphenylphosphine (2.10g, 8mmol) in THF (35mL). The mixture was stirred at room temperature for 72 hours, the THF removed in vacuo and the residue triturated with a mixture of hexanes and diethyl ether. The mixture was filtered, the filtrate concentrated and subjected to chromatography on a column of silica gel using a mixture of hexanes and ethyl acetate (3:2) as eluent. Elution gave methyl 2,5-dioxo-3,4-diphenyl-1-imidazolidinenonanoate (2.78g, 82%), mp 69-72°C.


20 Anal. Calcd. for $C_{25}H_{30}N_2O_4$: C, 71.07; H, 7.16; N, 6.65. Found: C, 71.13; H, 7.19; N, 6.66%.
¹H-NMR (CDCl₃) delta: 1.20 to 1.40 (8H, m), 1.50 to 1.70 (4H, m), 2.25 (2H, t, J=6Hz), 3.55 (2H, t, J=6Hz), 3.61 (3H, s), 5.41 (1H, s), 7.03 (1H, t, J=6.5Hz), 7.10 to 7.40 (7H, m) and 7.45 (2H, d, J=6.5Hz).

EXAMPLE 16

25

2,5-Dioxo-3,4-diphenyl-1-imidazolidinenonanoic acid

30



35


A mixture of methyl 2,5-dioxo-3,4-diphenyl-1-imidazolidinenonanoate (3.00g, 7mmol) and 6N HCl solution (30mL) was heated at reflux for 22 hours. The mixture was cooled, extracted with CH₂Cl₂ and the combined extracts washed with water and twice with saturated sodium chloride solution. After drying over sodium sulfate, the solvent was evaporated and the residue chromatographed on a column of silica gel using a mixture of hexanes and ethyl acetate (2:1) as eluent. Elution gave 2,5-dioxo-3,4-diphenyl-1-imidazolidinenonanoic acid (1.06g, 36%) after recrystallization from a mixture of hexanes, diethyl ether and CH₂Cl₂ (6:2:2), mp 111.5-112.5°C.

Anal. Calcd. for $C_{24}H_{28}N_2O_4$: C, 70.57; H, 6.91; N, 6.86. Found: C, 70.45; H, 7.05; N, 6.75%.
¹H-NMR (CDCl₃) delta: 1.20 to 1.40 (6H, m), 1.50 to 1.80 (4H, m), 2.14 (2H, t, J=6Hz), 3.61 (2H, t, J=6Hz), 5.42 (1H, s), 7.09 (1H, t, J=6Hz) and 7.15 to 7.60 (9H, m).

50 EXAMPLE 17

Methyl 5-(diphenylmethyl)-2H-tetrazole-2-nonanoate

55



10 A mixture of 5-(diphenylmethyl)-1H-tetrazole (5g, 21mmol) obtained according to J.W. Cusic, U.S. 3,155,666, methyl 9-bromononanoate (5.84g, 23mmol), potassium carbonate (3.50g, 25mmol), potassium iodide (catalytic quantity) and DMF (75mL) was stirred at 110 °C for 15 minutes. The mixture was cooled, diluted with water and extracted three times with diethyl ether. The combined extracts were washed three 15 times with water, dried over sodium sulfate and concentrated in vacuo to give an oil. Chromatography on a column of silica gel using a mixture of hexanes and diethyl ether (1:1) as eluent gave methyl 5-(diphenylmethyl)-2H-tetrazole-2-nonanoate (6.50g, 75%).


16 Anal. Calcd. for C₂₄H₃₀N₄O₂: C, 70.91; H, 7.44; N, 13.78. Found: C, 71.00; H, 7.57; N, 14.24%.

17 ¹H-NMR (CDCl₃) delta: 1.20 to 1.40 (8H, m), 1.59 (2H, quintet, J=7Hz), 1.96 (2H, quintet, J=7Hz), 2.28 (2H, t, J=7.5Hz), 3.64 (3H, s), 4.53 (2H, t, J=7Hz), 5.81 (1H, s) and 7.10 to 7.50 (10H, m).

EXAMPLE 18

5-(Diphenylmethyl)-2H-tetrazole-1-nonanoic acid

25



35 A mixture of methyl 5-(diphenylmethyl)-2H-tetrazole-1-nonanoate (5.00g, 12mmol), 5N NaOH solution (7.40mL, 36mmol) and methanol (100mL) was heated to reflux on a steam bath. After 20 minutes, the mixture was concentrated, diluted with water and 2N HCl solution and a white solid collected by filtration. Recrystallization from a mixture of CH₂Cl₂ and hexanes gave 5-(diphenylmethyl)-2H-tetrazole-1-nonanoic acid (4.40g, 90%), mp 68-70 °C.

40 Anal. Calcd. for C₂₃H₂₈N₄O₂: C, 70.38; H, 7.19; N, 14.27. Found: C, 70.37; H, 7.24; N, 14.35%.


41 ¹H-NMR (CDCl₃) delta: 1.28 (8H, bs), 1.58 (2H, quintet, J=6.5Hz), 1.97 (2H, quintet, J=6.5Hz), 2.29 (2H, t, J=7.5Hz), 4.55 (2H, t, J=7Hz), 5.81 (1H, s), 7.15 to 7.40 (10H, m) and 10.52 (1H, bs).

EXAMPLE 19

45

Methyl (3-[2-(4,5-diphenyl-2-thiazolyl)ethyl]phenoxy)acetate

50



55

A mixture of 3-[2-(4,5-diphenyl-2-thiazolyl)ethyl]phenol (3.65g, 10mmol), methyl bromoacetate (1.72g, 1.06mL, 11mmol) potassium carbonate (1.69g, 12mmol) and acetonitrile (60mL) was stirred at reflux for 90


minutes. The mixture was filtered and concentrated to leave an oil which was subjected to chromatography on a column of silica gel. Elution with a mixture of hexanes and diethyl ether (2:1) afforded methyl [3-[2-(4,5-diphenyl-2-thiazolyl)ethyl]phenoxy]acetate (3.63g, 82%) as an oil.

Anal. Calcd. for $C_{26}H_{23}NO_3S$: C, 72.70; H, 5.40; N, 3.26. Found: C, 73.13; H, 5.50; N, 3.26%.

5 1H -NMR ($CDCl_3$) delta: 3.10 to 3.20 (2H, m), 3.30 to 3.40 (2H, m), 3.78 (3H, s), 4.62 (2H, s), 6.76 (1H, dd, J = 8Hz, J' = 2.5Hz), 6.16 (1H, d, J = 2.5Hz), 6.92 (1H, d, J = 8Hz), 7.15 to 7.40 (9H, m) and 7.50 to 7.60 (2H, m).

EXAMPLE 20

10 [3-[2-(4,5-Diphenyl-2-thiazolyl)ethyl]phenoxy]acetic Acid




20 A mixture of methyl [3-[2-(4,5-diphenyl-2-thiazolyl)ethyl]phenoxy]acetate (2.70g, 6mmol), 5N NaOH solution (3.77mL, 18mmol) and methanol (40mL) was heated to reflux on a steam bath. After 20 minutes, the mixture was cooled, the methanol removed and the residue diluted with water and 2N HCl solution. The precipitate was filtered off, washed with water and dried in air. Recrystallization from a mixture of CH_2Cl_2 and hexanes provide [3-[2-(4,5-diphenyl-2-thiazolyl)ethyl]phenoxy]acetic acid (1.97g, 75%), mp 118-120 °C.

25 Anal. Calcd. for $C_{25}H_{21}NO_3S.0.1H_2O$: C, 71.96; H, 5.13; N, 3.36; H_2O , 0.43. Found: C, 71.69; H, 5.10; N, 3.06; H_2O 0.30%.

30 1H -NMR ($DMSO-d_6$) delta: 3.06 (2H, t, J = 8Hz), 3.31 (2H, t, J = 8Hz), 4.62 (2H, s), 6.73 (1H, d, J = 8Hz), 6.90 (2H, bs), 7.19 (1H, t, J = 8Hz) and 7.25 to 7.60 (10H, m).

EXAMPLE 21

35 Methyl [3-[2-(4,5-diphenyl-1H-imidazol-2-yl)ethyl]phenoxy]-acetate



45 A mixture of 3-[2-(1-ethoxyethyl)-4,5-diphenyl-1H-imidazo-2-yl]ethyl]phenol (6.60g, 16mmol), methyl bromoacetate (2.69g, 1.66mL, 18mmol), potassium carbonate (2.65g, 19mmol), potassium iodide (catalytic amount) and acetonitrile (100mL) was stirred at reflux for 2.5 hours. The mixture was filtered concentrated and the residual oil dissolved in methanol (120mL). Concentrated sulfuric acid (6 drops) was added and the mixture heated to reflux. After 75 minutes, concentrated H_2SO_4 (3 drops) was added and the mixture heated at reflux for a further 3.75 hours. The methanol was evaporated, the residue diluted with water and saturated sodium carbonate solution and the mixture extracted with CH_2Cl_2 . The combined extracts were dried over sodium sulfate and the solvent removed to leave an oil that crystallized on standing for 40 hours. Trituration with diethyl ether gave methyl [3-[2-(4,5-diphenyl-1H-imidazol-2-yl)ethyl]phenoxy]-acetate (5-15g, 78%). An analytical sample was prepared by recrystallizing a sample twice from a mixture of CH_2Cl_2 , diethyl ether and hexanes and had mp 123-125 °C.

50 Anal. Calcd. for $C_{26}H_{24}N_2O_3.0.8H_2O$: C, 73.16; H, 6.05; N, 6.57; H_2O 3.38. Found: C, 73.00; H, 5.78; N, 6.56; H_2O , 3.92%.

55 1H -NMR ($CDCl_3$) delta: 2.80 (4H, bs), 3.71 (3H, s), 4.52 (2H, s), 6.50 to 6.70 (3H, m), 6.94 (1H, t, J = 7.5Hz), 7.15 to 7.35 (8H, m), 7.40 to 7.45 (2H, m) and 10.13 (1H, bs).

EXAMPLE 22

[3-[2-(4,5-Diphenyl-1H-imidazol-2-yl)ethyl]phenoxyacetic Acid

5



10

A mixture of methyl [3-(2-(4,5-diphenyl-1H-imidazol-2-yl)ethyl]phenoxy]acetate (1.20g, 3mmol), 5N NaOH solution (1.74mL, 9mmol) and methanol (30mL) was heated to reflux on a steam bath for 20 minutes.

15 The solvent was removed, the residue diluted with water and acidified to pH = 1 with 2N HCl solution. A yellow solid was filtered off and subjected to chromatography on a column of silica gel using a mixture of chloroform and methanol (9:1) as eluent to give [3-[2-(4,5-diphenyl-1H-imidazol-2-yl)ethyl]phenoxy]-acetic acid (0.42g, 36%), mp 244-246 °C.

Anal. Calcd. for $C_{25}H_{22}N_2O_3 \cdot H_2O$: C, 72.10; H, 5.81; N, 6.36; H_2O 4.33. Found: C, 72.01; H, 5.72, N, 6.36; H_2O , 1.07%.


20 1H -NMR (DMSO-d $_6$) delta: 3.03 (4H, bs), 4.63 (2H, s), 6.73 (1H, d, J = 8Hz), 6.80 to 6.90 (2H, m), 7.20 (1H, t, J = 8Hz) and 7.25 to 7.60 (10H, m).

EXAMPLE 23

25

Methyl [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetate


30



35 and

Methyl [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetate

40



45

Sodium hydride (0.72g of a 50% dispersion in mineral oil, 15mmol) was washed twice with hexanes, covered with DMF (10mL) and 3,4-diphenyl-1H-pyrazole (2.99g, 13mmol) added. After gas evolution had 50 ceased, the mixture was stirred at 110 °C for 1 hour, cooled to room temperature and methyl [3-[2-[(4-methylphenyl)sulfonyl]oxy]ethyl]phenoxy]acetate (4.95g, 12mmol) in DMF (20mL) added. After stirring at room temperature for 15 hours, the mixture was poured onto water and extracted with ethyl acetate. The combined extracts were washed three times with water, once with saturated sodium chloride solution, dried over sodium sulfate and the solvent evaporated. The residual oil was chromatographed repeatedly on silica 55 gel using a mixture of hexane and ethyl acetate (4:1) as eluent. The less polar material was identified as methyl [3-[2-(3,4-diphenyl)-1H-pyrazol-1-yl]ethyl]phenoxy] acetate (1.71g, 30%).

Anal. Calcd. for $C_{26}H_{24}N_2O_3 \cdot 0.3H_2O$: C, 74.73; H, 5.94; N, 6.71; H_2O 1.29. Found: C, 74.42; H, 6.07; N, 6.55; H_2O , 0.65%.

EP 0 442 448 A2

¹H-NMR (CDCl₃) delta: 3.21 (2H, t, J = 7Hz), 3.75 (3H, s), 4.36 (2H, t, J = 7Hz), 4.56 (2H, s), 6.60 to 6.80 (3H, m), 7.10 to 7.40 (10H, m) and 7.45 to 7.55 (2H, m).

The more polar material was identified as methyl [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetate (0.66g, 11%).


5 Anal. Calcd. for C₂₆H₂₄N₂O₃: C, 75.71; H, 5.87; N, 6.80. Found: C, 75.84; H, 5.90; N, 6.71%.

¹H-NMR (CDCl₃) delta: 3.06 (2H, t, J = 7Hz), 3.75 (3H, s), 4.16 (2H, t, J = 7Hz), 4.48 (2H, s), 6.39 (1H, d, J = 1.5Hz), 6.56 (1H, d, J = 7.5Hz), 6.72 (1H, dd, J = 7.5 Hz, J' = 1.5Hz), 6.85 to 7.40 (11H, m) and 7.81 (1H, s).

10 EXAMPLE 24

[3-[2-(3,4-Diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetic Acid

15



20

A mixture of methyl [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)-ethyl]phenoxy]acetate (1.70g, 4mmol), 3N NaOH solution (4.2mL, 12mmol) and methanol (60mL) was heated on a steam bath for 10 minutes. The mixture was concentrated, diluted with water, made pH = 1 with dilute HCl solution and extracted with CH₂Cl₂. The combined extracts were washed with saturated sodium chloride solution, dried over sodium sulfate and the solvent evaporated. The residue was dissolved in CH₂Cl₂ and diluted with hexanes to give [3-[2-(3,4-diphenyl)-1H-pyrazol-1-yl]ethyl]phenoxy]acetic acid (1.27g, 77%), mp 147.5-149 °C.


Anal. Calcd. for C₂₅H₂₂N₂O₃.0.15H₂O: C, 74.86; H, 5.61; N, 6.98; H₂O, 0.67. Found: C, 74.55; H, 5.57; N, 6.96; H₂O, 0.43%.

30 ¹H-NMR (CDCl₃) delta: 3.18 (2H, t, J = 7.5Hz), 4.39 (2H, t, J = 7.5Hz), 4.57 (2H, s), 6.70 to 6.90 (3H, m), 7.10 to 7.40 (10H, m), 7.45 to 7.50 (2H, m) and 7.60 (1H, bs).

EXAMPLE 25

[3-[2-(4,5-Diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetic Acid

40



45

A mixture of methyl [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)-ethyl]phenoxy]acetate (0.42g, 1mmol), 3N NaOH solution (1.0mL, 3mmol) and methanol (30mL) was heated on a steam bath for 15 minutes before being concentrated in vacuo. The residue was diluted with water, 1N HCl solution added until pH = 1 and the mixture extracted with CH₂Cl₂. The combined organic phase was washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in CH₂Cl₂ and diluted with hexanes to furnish [3-[2-(4,5-diphenyl-1H-pyrazole-1-yl)ethyl]phenoxy]acetic acid (0.28g, 68%) m.p. 133-138 °C.


Anal. Calcd. for C₂₅H₂₂N₂O₃: C, 75.36; H, 5.57; N, 7.04. Found: C, 75.21; H, 5.48; N, 7.09%.

¹H-NMR (CDCl₃) delta: 2.99 (2H, t, J = 7Hz), 4.21 (2H, t, J = 7Hz), 4.57 (2H, s), 6.51 (1H, d, J = 7.5Hz), 55 6.57 (1H, s), 6.78 (1H, dd, J = 7.5Hz, J' = 2Hz), 6.95 to 7.45 (11H, m) and 7.85 (1H, s).

EXAMPLE 26

Methyl [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]acetate

5



10


A mixture of 3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenol (4.50g, 13mmol), methyl bromoacetate (2.23g, 1.375mL, 14.5mmol), potassium carbonate (2.19g, 16mmol), potassium iodide (catalytic amount) and acetonitrile (80mL) was stirred at reflux for 3 hours. The mixture was filtered, concentrated and the residue chromatographed on a column of silica gel prepared in a mixture of hexanes and diethyl ether (9:1). Subsequent elution with a mixture of hexanes and diethyl ether (1:1) furnished methyl [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]acetate (4.83g, 85%) as an oil.

Anal. Calcd. for $C_{26}H_{24}N_2O_3$: C, 75.71; H, 5.86; N, 7.79. Found: C, 75.46; H, 6.13; N, 7.12%.
 1H -NMR (CDCl₃) delta: 3.04 (4H, s), 3.77 (3H, s), 4.51 (2H, s), 6.30 (1H, s), 6.75 (1H, d, J=7Hz), 6.86 (1H, s), 6.93 (1H, d, J=7Hz), and 7.10 to 7.40 (11H, m).

EXAMPLE 27

25 [3-[2-(1,5-Diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]acetic Acid

30



35

A mixture of methyl [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]acetate (3.50g, 8.5mmol), 5N NaOH solution (5mL, 25mmol) and methanol (70mL) was heated to reflux on a steam bath for 15 minutes. The solvent was evaporated, the residue diluted with water and acidified with 2N HCl to pH=1. A white solid was filtered off and recrystallized from a mixture of hexanes and CH₂Cl₂ to give [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]acetic acid (2.85g, 84%), mp 125-127 °C.

Anal. Calcd. for $C_{25}H_{22}N_2O_3 \cdot 0.2H_2O$: C, 74.69; H, 5.62; N, 6.97; H₂O, 0.90. Found: C, 74.48; H, 6.08; N, 6.87; H₂O, 0.05%.


1H -NMR (DMSO-d₆) delta: 2.95 (4H, m), 4.65 (2H, s), 6.51 (1H, s), 6.73 (1H, d, J=7Hz) 6.85 to 6.95 (2H, m), 7.15 to 7.25 (5H, m), 7.25 to 7.40 (6H, m) and 12.65 (1H, bs).

45

EXAMPLE 28

Methyl [3-[2-(1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl)ethyl]phenoxy]acetate

50



55

Diethyl azodicarboxylate (2.73g, 2.50mL, 16mmol) was added to a stirred solution of 5,6-diphenyl-3(2H)-


pyridazinone (3.00g, 12mmol), methyl [3-(2-hydroxyethyl)phenoxy]acetate (2.80g, 13mmol) and triphenylphosphine (4.12g, 16mmol) in dry THF (75mL) maintained at 0 °C. The ice bath was removed and the mixture stirred at room temperature for 1.75 hours before removal of the solvent. The residue was chromatographed twice on columns of silica gel using mixtures of diethyl ether and hexanes (7:3) and then (3:2) as eluent to give methyl [3-[2-(1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl)ethyl]phenoxyacetate (5.12g, 98%), contaminated with 0.6 equivalents of 1,2-dicarbethoxy hydrazine, as a white foam.

Anal. Calcd. for $C_{27}H_{24}N_2O_4 \cdot 0.3H_2O \cdot 0.6C_6H_{12}N_2O_4$: C, 66.64; H, 5.82; N, 8.13; H_2O , 0.98. Found: C, 66.45; H, 5.60; N, 7.73; H_2O , 0.42%.
¹H-NMR (CDCl₃) delta: 1.24 (3H, t, J = 7Hz), 3.17 (2H, t, J = 8Hz), 3.76 (3H, s), 4.17 (2H, q, J = 7Hz), 4.49 (2H, t, J = 8Hz), 4.59 (1H, s), 6.77 (1H, dd, J = 8 Hz, J' = 2.5 Hz), 6.83 (1H, d, J = 2.5Hz), 6.93 (1H, s), 6.93 (1H, m), 7.00 to 7.10 (4H, m) and 7.15 to 7.40 (8H, m).

EXAMPLE 29

15 [3-[2-(1,6-Dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl)ethyl]phenoxy]acetic Acid

20



25 A mixture of methyl [3-[2-(1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl)ethyl]phenoxy]acetate (4.60g, 11mmol), 5N NaOH solution (3.20mL, 32mmol) and methanol (80mL) was heated to reflux on a steam bath. After 25 minutes, the methanol was evaporated, the residue diluted with water and acidified to pH = 1 with 2N HCl solution. A white solid was filtered off and dissolved in CH₂Cl₂. Addition of diethyl ether gave [3-[2-(1,6-dihydro-6-oxo-3,4-diphenyl)-1-pyridazinyl]ethyl]phenoxy]acetic acid hydrate dichloromethane solvate (2.60g, 58%), mp 165-167 °C.

30 Anal. Calcd. for $C_{26}H_{22}N_2O_4 \cdot 0.1H_2O \cdot CH_2Cl_2$: C, 63.20; H, 4.76; N, 5.46; H_2O , 0.35. Found: C, 63.41; H, 4.69; N, 5.44; H_2O , 0.14%.

¹H-NMR (DMSO-d₆) delta: 3.06 (2H, t, J = 7.5Hz), 4.37 (2H, t, J = 7.5Hz), 4.62 (1H, s), 5.74 (2H, s), 6.65 to 6.90 (3H, m), 6.94 (1H, s), 7.00 to 7.45 (11H, m) and 12.96 (1H, bs).


35

EXAMPLE 30

Methyl [3-[2-(2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl)ethyl]phenoxy]acetate

40

45



50 Diethyl azodicarboxylate (2.72g, 2.50mL, 16mmol) was added to a stirred solution of 5,6-diphenyl-1,2,4-triazol-3(2H)-one (3.00g, 12mmol), triphenylphosphine (4.11g, 16mmol) and methyl [3-(2-hydroxyethyl)phenoxy]acetate (2.78g, 13mmol) in dry THF (75mL) maintained at 0 °C under an atmosphere of nitrogen. The ice bath was removed and the mixture stirred at room temperature for 3 hours. The solvent was evaporated and the residue chromatographed twice on columns of silica gel using a mixture of diethyl ether and hexanes (7:3) as eluent to give methyl [3-[2-(2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl)ethyl]phenoxy]acetate (6.40g, 90%) as a yellow foam.


55 Anal. Calcd. for $C_{25}H_{23}N_3O_4 \cdot 0.5H_2O$: C, 69.33; H, 5.38; N, 9.33; H_2O , 1.99. Found: C, 69.23; H, 5.19; N, 9.56; H_2O , 0.15%.

¹H-NMR (CDCl₃) delta: 3.19 (2H, t, J = 7.5Hz), 3.72 (3H, s), 4.45 (2H, t, J = 7.5Hz), 4.56 (1H, s), 6.70 to 6.80 (2H, m), 6.88 (1H, d, J = 7.5Hz), 7.10 to 7.50 (11H, m).

EXAMPLE 31

[3-[2-(2,3-Dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl)ethyl]phenoxy]acetic Acid

5



10

A mixture of methyl [3-[2-(2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl)ethyl]phenoxy]acetate (4.00g, 9mmol), 5N NaOH (3.70mL, 18mmol) and methanol (60mL) was heated to reflux on a steam bath. After 20 minutes, the methanol was evaporated, the residue diluted with water and acidified with 2N HCl solution. A yellow solid was filtered off and recrystallized from a mixture of hexanes and CH_2Cl_2 to give [3-[2-(2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl)ethyl]phenoxy]acetic acid (2.79g, 72%), mp 179-182°C.


Anal. Calcd. for $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_4$: 0.5H₂O: C, 68.80; H, 5.09; N, 9.63; H₂O, 2.06. Found: C, 68.81; H, 4.79; N, 8.64; H₂O, 0.51%.

20 $^1\text{H-NMR}$ (DMSO-d₆) delta: 3.10 (2H, t, $J = 7.5\text{Hz}$), 4.36 (2H, t, $J = 7.5\text{ Hz}$), 4.62 (2H, s), 6.70 to 6.95 (3H, m), 7.10 to 7.60 (11H, m) and 12.97 (1H, bs).

EXAMPLE 32

Methyl [3-[2-[5-(diphenylmethyl)-2H-tetrazol-2-yl]ethyl]phenoxy]acetate

30



35

Diethyl azodicarboxylate (0.96g, 5.5mmol) was added to a stirred solution of 5-(diphenylmethyl)-2H-tetrazole (1.00g, 4.2mmol), methyl [3-(2-hydroxyethyl)-phenoxy]acetate (0.98g, 4.6mmol) and triphenylphosphine (1.44g, 5.5mmol) in dry THF (17mL) cooled to 0°C in an ice bath. The ice bath was removed and the mixture stirred at room temperature for 1 hour before the solvent was evaporated. The residue was chromatographed on a column of silica gel using a mixture of hexanes and ethyl acetate (3:1) to give methyl [3-[2-[5-(diphenylmethyl)-2H-tetrazol-2-yl]ethyl]phenoxy]acetate (1.06g, 58%) as a colorless oil.

Anal. Calcd. for $\text{C}_{25}\text{H}_{24}\text{N}_4\text{O}_3$: C, 70.08; H, 5.65; N, 13.08. Found: C, 70.03; H, 5.73; N, 12.66%.


45 $^1\text{H-NMR}$ (CDCl_3) delta: 3.26 (2H, t, $J = 7.5\text{Hz}$), 3.78 (3H, s), 4.53 (2H, s), 4.79 (2H, t, $J = 7.5\text{Hz}$), 5.77 (1H, s), 6.65 to 6.80 (3H, m) and 7.10 to 7.40 (11H, m).

EXAMPLE 33

[3-[2-[5-(Diphenylmethyl)-2H-tetrazol-2-yl]ethyl]phenoxy]acetic Acid

50

55



5 A mixture of methyl [3-[2-[5-(diphenylmethyl)-2H-tetrazol-2-yl]ethyl]phenoxy]acetate (0.84g, 2mmol), 3N NaOH solution (2.00mL, 6mmol) and methanol (35mL) was heated for 10 minutes on a steam bath. The methanol was evaporated, the residue diluted with water and acidified to pH = 1 with 1N HCl solution. The mixture was extracted three times with CH_2Cl_2 , the combined extracts washed with saturated sodium chloride solution and dried over sodium sulfate. Evaporation of the solvent left an oil which was chromatographed on a column of silica gel using a mixture of chloroform and methanol (93:7) as eluent to give [3-[2-[5-(diphenylmethyl)-2H-tetrazol-2-yl]ethyl]phenoxy]acetic acid (0.50g, 61%) as a colorless oil.

6 Anal. Calcd. for $\text{C}_{24}\text{H}_{22}\text{N}_4\text{O}_3 \cdot 0.2\text{H}_2\text{O}$: C, 68.96; H, 5.41; N, 13.41; H_2O , 0.86. Found: C, 68.58; H, 5.42; N, 13.05; H_2O , 0.54%.

10 $^1\text{H-NMR}$ (CDCl_3) delta: 3.25 (2H, t, $J = 7.5\text{Hz}$), 4.54 (2H, s), 4.78 (2H, t, $J = 7.5\text{Hz}$), 5.80 (1H, s), 6.60 to 6.85 (3H, m), 7.20 to 7.40 (11H, m) and 9.62 (1H, bs).


EXAMPLE 34

15 Preparation of Intermediates

(34-1)

3-[2-(4,5-Diphenyl-2-thiazolyl)ethyl]phenol

20



25

n-Butyllithium (1.53g, 24mmol) in hexane (9.5mL) was added dropwise to a stirred solution of 2-methyl-4,5-diphenylthiazole (5g, 20mmol) in dry THF (150mL) maintained at -78°C under an atmosphere of nitrogen. After 25 minutes a solution of [3-(bromomethyl)phenoxy]dimethyl(1,1-dimethylethyl)silane (6.60g, 22mmol) in THF (10mL) was added dropwise, the mixture stirred at -78°C for 10 minutes and then allowed to warm to room temperature. The reaction mixture was poured onto saturated ammonium chloride solution, extracted with CH_2Cl_2 , the extracts combined, dried over sodium sulfate and concentrated in vacuo to leave an oil which was dissolved in THF (25mL). A solution of tetra-n-butylammonium fluoride (6.77g, 26mmol) in THF (25.86mL) was added and the mixture stirred at room temperature for 30 minutes before being diluted with 1N HCl solution (100mL). The mixture was extracted with CH_2Cl_2 , the combined extracts dried over sodium sulfate and concentrated to leave an oil. Chromatography on a column of silica gel using a mixture of hexanes and diethyl ether (2:1) as eluent furnished 3-[2-(4,5-diphenyl-2-thiazolyl)ethyl]phenol (4.13g, 58%), mp 166-168 $^\circ\text{C}$ after recrystallization from a mixture of hexanes and CH_2Cl_2 .


Anal. Calcd. for $\text{C}_{23}\text{H}_{19}\text{NOS}$: C, 77.28; H, 5.36; N, 3.92. Found: C, 77.22; H, 5.46; N, 3.71%.

40 $^1\text{H-NMR}$ (CDCl_3) delta: 3.04 to 3.14 (2H, m), 3.20 to 3.40 (2H, m), 5.89 (1H, s), 6.60 to 6.75 (2H, m) 6.80 to 6.90 (1H, m), 7.13 (1H, t, $J = 8\text{Hz}$), 7.20 to 7.45 (8H, m) and 7.50 to 8.00 (2H, m).

(34-2)

45 1-(1-Ethoxyethyl)-2-methyl-4,5-diphenyl-1H-imidazole

50



55

A mixture of 2-methyl-4,5-diphenylimidazole (3.00g, 13mmol), ethyl vinyl ether (9.23g, 12.30mL,


130mmol) and hydroquinone (0.14g, 1.2mmol) was heated at 180 °C in a sealed vessel for 17 hours. The excess ethyl vinyl ether was evaporated and the residue chromatographed on a column of silica gel using a mixture of diethyl ether and hexanes (3:2) as eluent. Elution gave 1-(1-ethoxyethyl)-2-methyl-4,5-diphenyl-1H-imidazole (2.68g, 68%), mp 87-89 °C.

5 Anal. Calcd. for $C_{20}H_{22}N_2O$: C, 78.40; H, 7.24; N, 9.14. Found: C, 78.64; H, 7.31; N, 9.56%.

10 1H -NMR ($CDCl_3$) delta: 1.09 (3H, t, J = 7Hz), 1.55 (3H, d, J = 6Hz), 2.62 (3H, s), 3.20 and 3.35 (2H, m), 5.07 (1H, q, J = 6Hz) and 7.00 to 7.50 (10H, m).

(34-3)

15 3-[2-[1-(1-Ethoxyethyl)-4,5-diphenyl-1H-imidazol-2-yl]ethyl]-phenol



20


n-Butyllithium (3.89g, 61mmol) in hexane (24.31mL) was added dropwise to a stirred solution of 1-(1-ethoxyethyl)-2-methyl-4,5-diphenyl-1H-imidazole (15.50g, 51mmol) in dry THF (300mL) maintained at -78 °C under an atmosphere of nitrogen. The mixture was stirred for 45 minutes and [3-(bromomethyl)-phenoxy]-25 dimethyl(1,1-dimethylethyl)silane (16.77g, 50mmol) added dropwise. After 10 minutes, the mixture was poured onto water, extracted with CH_2Cl_2 , the extracts combined and dried over sodium sulfate. Evaporation of the solvent left an oil which was dissolved in THF (75mL) and a solution of tetra-n-butylammonium fluoride (17.22g, 66mol) in THF (65mL) added. The solution was stirred at room temperature for 30 minutes, the solvent evaporated and the residue diluted with water. After addition of 2N HCl solution (about 20mL) to 30 pH = 5, the mixture was extracted with CH_2Cl_2 . The combined extracts were dried over sodium sulfate, concentrated in vacuo and the residual material chromatographed on a column of silica gel. Elution with a mixture of diethyl ether and hexanes (1:1) gave 3-[2-[1-(1-ethoxyethyl)-4,5-diphenyl-1H-imidazol-2-yl]ethyl]-phenol (8.18g, 39%), mp 165.5-167 °C after recrystallization from a mixture of CH_2Cl_2 and hexanes.

35 Anal. Calcd. for $C_{27}H_{28}N_2O_2\cdot 0.4H_2O$: C, 77.27; H, 6.92; N, 6.68; H_2O , 1.72. Found: C, 77.31; H, 6.93; N, 6.29; H_2O , 1.75%.

40 1H -NMR ($CDCl_3$) delta: 0.99 (3H, t, J = 7Hz), 1.45 (3H, d, J = 6Hz), 3.00 to 3.40 (6H, m), 5.05 (1H, q, J = 6Hz), 6.60 (1H, dd, J = 7Hz, J' = 1.5Hz), 6.74 (2H, m), 7.00 to 7.30 (4H, m), 7.30 to 7.45 (4H m), 7.45 to 7.60 (3H, m) and 9.30 (1H, s).

45 (34-4)

50 5-[3-[Dimethyl(1,1-dimethylethyl)siloxyl]phenyl]-1-phenyl-1,3-pentanedione



55 Sodium hydride (2.13g of a 50% dispersion in mineral oil, 44mmol) was washed twice with hexanes, covered with dry THF (150mL) and 1-benzoylacetone (6.00g, 37mmol) added portionwise. The mixture was stirred at room temperature under an atmosphere of nitrogen for 10 minutes to give a slurry which was cooled to -20 °C. n-Butyllithium (2.60g, 40mmol) in hexane (16.3mL) was added dropwise to provide a solution which was stirred for 20 minutes prior to the dropwise addition of [3-(bromomethyl)phenoxy]-dimethyl(1,1-dimethylethyl)silane (11.17g, 37mmol). After 15 minutes, the mixture was poured onto satu-


rated ammonium chloride solution and extracted with CH_2Cl_2 . The combined extracts were dried over sodium sulfate, concentrated in vacuo and the residual oil chromatographed on a column of silica gel. Elution with a mixture of hexanes and diethyl ether (9:1) gave 5-[3-[dimethyl(1,1-dimethylethyl)siloxy]phenyl]-1-phenyl-1,3-pentanedione (9.00g, 63%).

5

(34-5)

3-[2-(1,5-Diphenyl-1H-pyrazol-3-yl)ethyl]phenol

10



15


A mixture of 5-[3-[dimethyl(1,1-dimethylethyl)siloxy]phenyl]-1-phenyl-1,3-pentanedione (8.80g, 23mmol), phenylhydrazine (2.73g, 2.50mL, 25mL), pyridine (3mL) and methanol (70mL) was stirred at room temperature. After 20 hours, phenylhydrazine (0.3mL) was added and stirring continued for an additional 7 hours. The solvent was evaporated and the residue chromatographed on a column of silica gel using a mixture of hexanes and diethyl ether (9:1) as eluent to give 3-[2-[3-(dimethyl(1,1-dimethylethyl)siloxy)phenyl]-1-(diphenylmethyl)-5-phenyl-1H-pyrazole (10.27g, 98%) of which (9.20g, 20mmol) was dissolved in THF (180mL). A solution of tetra n-butylammonium fluoride (6.89g, 26mmol) in THF (26.34mL) was added and the mixture stirred at room temperature for 30 minutes. The solvent was evaporated, the residue diluted with 1N HCl solution and extracted with CH_2Cl_2 . The combined extracts were dried over sodium sulfate and concentrated to give a white solid which was triturated with diethyl ether and filtered to give 3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenol (5.31g, 77%). An analytical sample recrystallized from ethanol had mp 211-212°C.

Anal. Calcd. for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}$: C, 81.15; 5.92; N, 8.23. Found: C, 80.90; H, 6.24; N, 8.22%.

30 $^1\text{H-NMR}$ (DMSO- d^6) delta: 2.87 (4H, bs), 3.35 (1H, s), 6.49 (1H, s), 6.58 (1H, dd, $J=7\text{Hz}$, $J'=1.5\text{Hz}$), 6.67 to 6.70 (2H, m), 7.07 (1H, t, $J=7\text{Hz}$), 7.10 to 7.30 (4H, m), and 7.30 to 7.50 (6H, m).

The compounds of the instant invention wherein HET₂ is the heterocyclic radical 4,5-diphenyl-1H-imidazol-2-yl are further characterized by Formula VIII

35




wherein R₁ is hydrogen, lower alkyl or an alkali metal ion and the radical -OCH₂CO₂R is attached in the 3 or 4 ring position.

45 Formula VIII compounds are obtained by a process comprising:

(a) hydrolyzing a compound of Formula IX


50




55

wherein R^a is lower alkyl; or

(b) esterifying a compound of Formula X



10 or;
 (c) alkylating 4,5-diphenyl-2-imidazolethiol with a compound of Formula XI




wherein R³ is lower alkyl and X is halogen or an aryl sulfonate.

20 The compounds of Formula VIII have pharmacological properties similar to those of Formula I and II compounds. In vitro inhibition of human platelet aggregation test results for the compounds of Examples 35 and 36 are given hereinafter.

25

TABLE 3
 Inhibition of Human Platelet Aggregation
 of Formula VIII Compounds (IC_{50} mcg/ml)




35

<u>Example</u>	<u>R₁</u>	<u>V_sADP mcg/ml</u>
35	CH ₃	0.42
40	H	0.41

45 EXAMPLE 35

Methyl [3-[[4,5-diphenyl-1H-imidazol-2-yl]thio]methyl]phenoxy]acetate



55


Sodium hydride (684 mg of a 50% dispersion, 14 mmol) was washed three times with hexane and

covered with DMF (60 mL). 4,5-Diphenyl-1-imidazolethiol (3g, 12 mmol) was added to afford a yellow solution after hydrogen evolution had ceased. Methyl (3-chloromethylphenoxy)acetate (2.68 g, 12.5 mmol) was added and the mixture stirred at room temperature for 1.5 hours and then at 100 °C for 0.5 hour. After cooling, the mixture was diluted with water and extracted with diethyl ether (3 times). The combined extracts were washed with water (3 times), dried and concentrated in vacuo. Crystallization of the residual solid from a mixture of hexanes and CH_2Cl_2 afforded methyl [3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]methyl]phenoxy]acetate (3.00 g, 58%), m.p. indistinct.

Anal. Calcd. for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_3\text{S}$: C, 69.75; H, 5.15; N, 6.51. Found: C, 69.79; H, 5.23; N, 6.24.
 $^1\text{H-NMR}$ (CDCl_3) delta: 3.72 (3H, s), 4.13 (2H, s), 4.56 (2H, s), 6.75 to 6.80 (3H, m) and 7.10 to 7.50 (12H, m).

EXAMPLE 36

15 [3-[(4,5-Diphenyl-1H-imidazol-2-yl)thio]methyl]phenoxy]acetic Acid




25 A mixture of methyl [3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]methyl]phenoxy]acetate (2.00 g, 4.6 mmol), lithium hydroxide monohydrate (586 mg, 14 mmol), methanol (35 mL) and water (10 mL) was stirred at room temperature for 2 hours. The solvent was evaporated, the residue diluted with water and 2N HCl solution added to pH=7. A white solid was filtered off and recrystallized from aqueous DMF to give [3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]methyl]phenoxy]acetic acid (1.33 g, 69%), m.p. 233-235 °C.

30 Anal. Calcd. for $\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_3\text{S}$: C, 69.21; H, 4.84; N, 6.73. Found: C, 69.43; H, 4.92; N, 6.92.
 $^1\text{H-NMR}$ ($\text{DMSO-}D_6$) delta: 4.34 (2H, s), 4.60 (2H, s), 6.77 (1H, dd, $J=8\text{Hz}$, $J'=2\text{Hz}$), 6.90 to 7.00 (2H, m), 7.05 to 7.60 (12H) and 12.40 to 13.00 (1H, bs).

35 Claims

1. A compound of Formula I



wherein

n is 6 to 9;

R is hydrogen or lower alkyl or an alkali metal ion; and


HET₁ is a heterocyclic radical selected from the group consisting of

45


50

55

5




10 (a) 3,4-diphenyl-1H-pyrrrol-1-yl.




(b) 1,6-dihydro-6-oxo-3,4-diphenyl-1H-pyridazinyl.

15




20 (c) 2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl.




(d) 1-oxo-4,5-diphenyl-2H-pyrimidin-1-yl.

25




30 (e) 2,5-dioxo-3,4-diphenylimidazolidin-1-yl.



(f) 5-(diphenylmethyl)-2H-tetrazol-2-yl.

40



45

(g) 4,5-diphenyl-2-thiazolyl.

(h) 4,5-diphenyl-1H-imidazol-2-yl, and


50



55

(i) 1,5-diphenyl-1H-pyrazol-3-yl



2. A compound of Formula II



wherein



10 R_1 is hydrogen, lower alkyl or an alkali metal ion, and the radical $-OCH_2CO_2R_1$ is attached in
the 3 or 4 ring position;

15 HET_2 is a heterocyclic radical selected from the group consisting of





20 (a) 4,5-diphenyl-2-thiazoyl,

(b) 4,5-diphenyl-1H-imidazol-2-yl,





30 (c) 3,4-diphenyl-1H-pyrazol-1-yl,

(d) 4,5-diphenyl-1H-pyrazol-1-yl,



40 (e) 1,5-diphenyl-1H-pyrazol-3-yl,


(f) 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl,



55 (g) 2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl, and

(h) 5-(diphenylmethyl)-2H-tetrazol-2-yl.

3. A compound of Formula VIII



10 wherein R_1 is hydrogen, lower alkyl or an alkali metal ion, and the radical $-OCH_2CO_2R_1$ is attached in the 3 or 4 ring position.


4. The compounds according to claim 1 which are methyl 3,4-diphenyl-1H-pyrrole-1-nonanoate;
15 3,4-diphenyl-1H-pyrrole-1-nonanoic acid;
methyl 6-oxo-3,4-diphenyl-1(6H) pyridazinenonanoate;
20 oxo-3,4diphenyl-1(6H)-pyridazinenonanoic acid;
methyl 6-oxo-3,4-diphenyl-1(6H)-pyridazinyloctanoate;
25 6-oxo-3,4-diphenyl-1(6H)-pyridazinyl-octanoic acid;
methyl 3-oxo-5,6-diphenyl-1,2,4-triazine-2(3H)-nonanoate;
30 3-oxo-5,6-diphenyl-1,2,4-triazine-2(3H)-nonanoic acid;
methyl 3-oxo-5,6-diphenyl-1,2,4-triazine-2(3H)-octanoate ;
35 3-oxo-5,6-diphenyl-1,2,4-triazine-2(3H)-octanoic acid ;
methyl 2-oxo-4,5-diphenyl-1(2H)-pyrimidinenonanoate ;
2-oxo-4,5-diphenyl-1(2H)-pyrimidinenonanoic acid ;
40 methyl 2-oxo-4,5-diphenyl-1(2H)-pyrimidineoctanoate ;
2-oxo-4,5-diphenyl-1(2H)pyrimidineoctanoic acid ;
45 methyl 2,5-dioxo-3,4-diphenyl-1-imidazolidinenonanoate;
2,5-dioxo-3,4-diphenyl-1-imidazolidinenonanoic acid;
methyl 5-(diphenylmethyl)-2H-tetrazole-2-nananoate; and
5-(diphenylmethyl)-2H-tetrazole-1-nonanoic acid.
50 5. The compounds according to claim 2 which are methyl [3-[2-(4,5-diphenyl-2-thiazolyl)ethyl]phenoxy]-acetate;
[3-[2-(4,5-diphenyl-2-thiazolyl)ethyl]phenoxy]acetic acid;
55 methyl [3-[2-(4,5-diphenyl-1H-imidazol-2-yl)ethyl]phenoxy]acetate;
[3-[2-(4,5-diphenyl-1H-imidazol-2-yl)ethyl]phenoxyacetic acid;

methyl [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetate;
 methyl [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetate ;
 5 [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetic acid ;
 [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]acetic acid ;
 methyl [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]acetate ;
 10 [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]acetic acid ;
 methyl [3-[2-(1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl)ethyl]phenoxy]acetate ;
 15 [3-[2-(1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl)ethyl]phenoxy]acetic acid ;
 methyl [3-[2-(2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl)ethyl]phenoxy]acetate;
 [3-[2-(2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl)ethyl]phenoxy]acetic acid;
 20 methyl [3-[2-(5-(diphenylmethyl)-2H-tetrazol-2-yl)ethyl]phenoxy]acetate ; and
 [3-[2-(5-(diphenylmethyl)-2H-tetrazol-2-yl)ethyl]phenoxy]-acetic acid .
 25 6. The compounds according to claim 3 which are methyl [3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]methyl]-
 phenoxy]acetate ; and
 [3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]methyl]phenoxy]acetic acid.
 30 7. A process for preparing the compounds of Formula I as defined in claims 1 and 4 comprising:
 (a) hydrolyzing a compound of Formula (I^a)

$$\text{HET}_1-(\text{CH}_2)_n\text{CO}_2\text{R}^a \quad (\text{I}^a)$$
 35 wherein HET₁ is as defined above, n is 6-9 and R^a is lower alkyl, or
 (b) esterifying a compound of Formula (I^b)


$$\text{HET}_1-(\text{CH}_2)_n\text{CO}_2\text{H} \quad (\text{I}^b)$$
 40 wherein HET₁ is as defined above and n is 6-9 with a lower alkanol, or
 (c) alkylating HET₁-H wherein HET₁ is as defined above with a compound of Formula (III)

$$\text{X}-(\text{CH}_2)_n\text{CO}_2\text{R}^a \quad (\text{III})$$
 45 wherein X is halogen, preferably bromine, n is 6 to 9, and R^a is lower alkyl.
 8. A process for preparing the compounds of formula II as defined in claims 2 and 5 comprising
 (a) hydrolyzing a compound of Formula II^a
 50




55

wherein Het₂ is as defined above and R^a is lower alkyl; or
 (b) esterifying a compound of Formula II^b




wherein HET₂ is as defined above; or

(c) alkylating HET₂-H wherein HET₂ is as defined above with a compound of Formula (V)




wherein R^a is lower alkyl and X is halogen or an aryl sulfonate; or

(d) alkylating a compound of Formula (VI)




wherein HET₂ is as defined above with BrCH₂CO₂R^a wherein R^a is lower alkyl; or

(e) hydrolyzing a compound of Formula VII




40 9. A process for preparing the compound of Formula VIII as defined in claims 3 and 6, comprising:

(a) hydrolyzing a compound of Formula IX




50 wherein R^a is lower alkyl; or

(b) esterifying a compound of Formula X



10
or;
(c) alkylating 4,5-diphenyl-2-imidazolethiol with a compound, of Formula XI



wherein R₁^a is lower alkyl and X is halogen or an aryl sulfonate.

10. A pharmaceutical composition comprising at least one compound according to anyone of claims 1 to 6
20 and a pharmaceutically acceptable carrier.

11. A process for preparing the pharmaceutical composition of claim 10 which comprises incorporating at least one compound according to anyone of claims 1 to 6 into a pharmaceutically acceptable carrier.

25 12. The use of at least one compound according to anyone of claims 1 to 6 for preparing a pharmaceutical composition for inhibiting blood platelet aggregation.

30


35

40

45

50

55





Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number: 0 442 448 A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 91101958.6

⑮ Int. Cl. 5. C07D 207/327, C07D 237/14,
C07D 253/07, C07D 239/36,
C07D 233/72, C07D 257/04,
C07D 277/30, C07D 233/64,
C07D 231/12, C07D 233/84,
A61K 31/40

⑭ Date of filing: 12.02.91

⑯ Priority: 13.02.90 US 479507
13.02.90 US 479508
13.02.90 US 479563
13.02.90 US 479561
13.02.90 US 479564
13.02.90 US 479559
13.02.90 US 479560
13.02.90 US 479506
20.06.90 US 540988
13.02.90 US 479505

⑰ Date of publication of application:
21.08.91 Bulletin 91/34

⑱ Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

⑲ Date of deferred publication of the search report:
12.08.92 Bulletin 92/33



⑳ Applicant: Bristol-Myers Squibb Company
345 Park Avenue
New York, N.Y. 10154(US)

㉑ Inventor: Meanwell, Nicholas
2 Spice Hill Drive
East Hampton, Connecticut 06424(US)

㉒ Representative: Kinzebach, Werner, Dr. et al
Patentanwälte Reitschäffer, Kinzebach und
Partner Sternwartstrasse 4 Postfach 86 06 49
W-8000 München 86(DE)

㉓ Heterocyclic carboxylic acids and esters.

㉔ Heterocyclic acids and esters useful as inhibitors of mammalian blood platelet aggregation characterized by Formula I, II and VIII are disclosed.



EP 0 442 448 A3

EP 0 442 448 A3

Formula I compounds are those wherein n is 6-9, R is hydrogen, lower alkyl or an alkali metal ion, and HET₁ is heterocyclic radical selected from the group consisting of 3,4-diphenyl-1H-pyrrol-1-yl, 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl, 2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl, 1-oxo-4,5-diphenyl-2H-pyrimidin-1-yl, 2,5-dioxo-3,4-diphenylimidazolidin-1-yl, 5-(diphenylmethyl)-2H-tetrazol-2-yl, 4,5-diphenyl-2-thiazoyl, 4,5-diphenyl-1H-imidazol-2-yl, and 1,5-diphenyl-1H-pyrazol-3-yl.

Formula II compounds are those wherein R₁ is hydrogen, lower alkyl or an alkali metal ion, and the radical -OCH₂CO₂R is attached in the 3 or 4 ring position; and HET₂ is a heterocyclic radical selected from the group consisting of 4,5-diphenyl-2-thiazoyl, 4,5-diphenyl-1H-imidazol-2-yl, 3,4-diphenyl-1H-pyrazol-1-yl, 4,5-diphenyl-1H-pyrazol-1-yl, 1-5-diphenyl-1H-pyrazol-3-yl, 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl, 2,3-dihydro-3-oxo-5,6-diphenylmethyl-1,2,3-triazin-2-yl, and 5-(diphenylmethyl)-2H-tetrazol-2-yl.

Formula VIII compounds are those wherein R₁ is hydrogen, lower alkyl or an alkali metal ion, and the radical -OCH₂CO₂R is attached in the 3 or 4 ring position.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 10 1958
PAGE1

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. CL.S)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.S)
A,D	US-A-4 563 477 (F.S. MALDONADO ET AL.) * claims 1,2 *	1,10,12	C07D207/327 C07D237/14 C07D253/07 C07D239/36 C07D233/72 C07D257/04 C07D277/30 C07D233/64 C07D231/12 C07D233/84 A61K31/40 A61K31/41 A61K31/415 A61K31/425 A61K31/50
A,D	US-A-4 168 315 (R.H. RYNBRANDT ET AL.) * claims 1,16 *	1,10,12	
A,D	US-A-4 486 443 (A.G. CALDWELL ET AL.) * claims 1,14,16,33,44 *	1,10,12	
A	EP-A-0 054 593 (SANDFT, S.A.) * claims 1,3 *	1,10,12	
A,D	US-A-4 330 550 (H.-H. LAUTENSCHLAGER ET AL.) * column 3, line 49 - line 59; claim 1 *	1,12	
A	EP-A-0 143 461 (KAKEN PHARMACEUTICAL CO., LTD.) * abstract; claim 1 *	1,12	
A,D	US-A-4 460 598 (H.-H. LAUTENSCHLAGER ET AL.) * claims 1,21 *	1,10	
A,D	US-A-4 677 105 (G. PITET ET AL.) * claims 1,3 *	1,10	TECHNICAL FIELDS SEARCHED (Int. CL.S)
A,D	US-A-4 826 868 (M.P. WACHTER ET AL.) * claims 1,12 *	1,10	C07D
A,D	US-A-2 712 542 (J.A. KING ET AL.) * column 3, line 8 - line 13; examples *	1,10	
A,D	US-A-3 453 285 (S. HAYAO ET AL.) * abstract; claim 1 *	1,10	
A,D	US-A-3 506 679 (J.F. CAVALLA ET AL.) * abstract; claim 1 *	1,10	
A,D	US-A-4 853 404 (N. TAKAMURA ET AL.) * claims 1,10 *	2,10	
		-/-	
The present search report has been drawn up for all claims			
Place of search BERLIN	Date of completion of the search 10 JUNE 1992	Examiner Christian Hess	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : technological background O : non-written disclosure P : intermediate document S : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 10 1958
PAGE2

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)						
A	US-A-4 734 421 (M. L. HAMMOND ET AL.) * example 7 *	3							
			TECHNICAL FIELDS SEARCHED (Int. CL.5)						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>BERLIN</td> <td>10 JUNE 1992</td> <td>Christian Hass</td> </tr> </table> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons □ : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	BERLIN	10 JUNE 1992	Christian Hass
Place of search	Date of completion of the search	Examiner							
BERLIN	10 JUNE 1992	Christian Hass							

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 December 2003 (04.12.2003)

PCT

(10) International Publication Number
WO 03/099793 A1

(51) International Patent Classification⁷: C07D 231/12,
261/08, 401/04, 413/12, A61K 31/4155, 31/415, 31/42,
31/422, 31/4439, C07D 231/14, 231/20, 231/22, 401/14,
403/04, 403/14

Chuo-ku, Kobe-shi, Hyogo 651-0078 (JP). FUKATSU,
Kohji [JP/JP]; 8-4, Tsukushigaoka 5-chome, Kita-ku,
Kobe-shi, Hyogo 651-1212 (JP).

(21) International Application Number: PCT/JP03/06389

(74) Agent: TAKASHIMA, Hajime; Fujimura Yamato Scimci
Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi,
Osaka 541-0044 (JP).

(22) International Filing Date: 22 May 2003 (22.05.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:
2002-151405 24 May 2002 (24.05.2002) JP
2002-287161 30 September 2002 (30.09.2002) JP
2003-16748 24 January 2003 (24.01.2003) JP

(71) Applicant (for all designated States except US): TAKEDA
CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1,
Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka
541-0045 (JP).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): MAEKAWA,
Tsuyoshi [JP/JP]; 2-21, Ioi 1-chome, Ikaruga-cho,
Ikoma-gun, Nara 636-0124 (JP). HARA, Ryoma [JP/JP];
18-D75-305, Tsukumodai 5-chome, Saita-shi, Osaka
565-0862 (JP). ODAKA, Hiroyuki [JP/JP]; 12-12, Kat-
suragi 2-chome, Kita-ku, Kobe-shi, Hyogo 651-1223 (JP).
KIMURA, Hiroyuki [JP/JP]; 2-20-808, Ohamanaka-
machi 1-cho, Sakai-shi, Osaka 590-0975 (JP). MIZU-
FUNE, Hideya [JP/JP]; 2-13-603, Yagumodori 2-chome,

A1

(54) Title: 1,2-AZOLE DERIVATIVES WITH HYPOGLYSEMIC AND HYPOLIPIDEMIC ACTIVITY



WO 03/099793

A1

(57) Abstract: A compound represented by the formula wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, -O-, -S- and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR₄ (R₄ is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.